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CHAPTER-1 
INTRODUCTION 
The oral route of drug administration is the most important method of administering 
drugs for systemic effect. The 90% of drugs used to produce systemic effects are 
administered by oral route. Among the drugs that are administered orally, solid oral dosage 
form such as tablet represent the preferred class of products. The reasons for this preference 
are as follows. Tablet is an unit dosage form in which one usual dose of the drug has been 
accurately placed by compression. Liquid oral dosage forms, such as syrups, suspensions, 
emulsions, solutions and elixirs are usually designed to contain one (or) more dose of 
medication in 5 to 30ml. The patient is then asked to measure his or her own medications 
using, tablespoon or other measuring device. Such dosage measurements are typically in 
error by a factor ranging from 20-50% when the drug is self-administered by the patient.  
1.1. TABLETS1  
Tablet is defined as a compressed solid dosage form containing medicaments with or 
without excipients. According to Indian pharmacopoeia, pharmaceutical tablets are solid, flat 
or biconvex dishes. Tablets are prepared by compressing a drug or a mixture of drugs, with 
or without diluents. They vary in shape and differ greatly in size and weight, depending on 
amount of medicinal substances and the intended mode of administration. It is the most 
popular dosage form and 70% of the total medicines are dispensed in the form of tablets. All 
medicaments are available in the tablet form except where it is difficult to formulate or 
administer. Although a variety of tablets exist, with few exceptions (primarily sugar 
lozenges) tablets are formed by the compression of a powder held within a confined space. 
The tablet consists of one or more drugs (active ingredients) as well as series of other 
substances used in the formulation of a complete preparation. Tablets are used mainly for 
systemic drug delivery but also for local drug action. For systemic use the drug must be 
released from the tablet. 
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1.1.1.Advantages of Tablets: 
 They are unit dosage form and they offer the greatest capabilities of all oral dosage 
forms for the greatest dose precision and the least content variability. 
 They offer lowest cost of all oral dosage forms. 
 They are the lightest and most compact oral dosage forms. 
 They are in general the easiest and cheapest to package and strip. 
 Product identification is potentially the simplest and cheapest, requiring no 
additional processing steps when employing an embossed or monogrammed punch 
face. 
 They may provide the greatest ease of swallowing with the least tendency for 
“hang up” above the stomach. 
 They lend themselves to certain special release profile products such as enteric or 
delayed release products. 
 Objectionable odour and bitter taste can be masked by coating technique. 
 Greatest chemical and microbial stability over all oral dosage forms. 
 They are better suited to large scale production than other unit oral dosage forms2,3 
1.1.2.Disadvantages of Tablets
4,5
: 
 Difficult to swallow in case of children and elderly patients. 
 Some drugs resist compression into dense compacts, owing to their amorphous 
nature or flocculent, low density character. 
 Drugs with poor wetting, slow dissolution properties, intermediate to large 
dosages, poor absorption in the GI tract or any combination of this features may be 
difficult or impossible to formulate and manufacture as a tablet. 
 Bitter tasting drugs, drugs with an objectionable odor or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation or entrapment prior to 
compression or the tablets may require coating.  
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1.2. ADDITIVES USED IN TABLETS 
Excipients are pharmacologically inactive substances included in the formulation which is 
used as a carrier of active ingredient
6
. The excipients used in the tablet formulation includes,
 
1. Diluents/fillers 
2. Binders 
3. Disintegrants 
4. Lubricants 
5. Glidants 
6. Anti-Adherents  
7. Miscellaneous 
Diluents
 
Diluents are used to increase the bulk content of the dosage form. This is done in a 
situation where the active constituent to be incorporated in the formulation is of less 
quantity. For example if the active ingredient is just 5 mg, in such a case a tablet of just 5 
mg is very difficult to manufacture and handle too, thus the bulk content is increased by 
addition of inactive excipients. Round tablets of weight 120mg to 700mg and oval tablets of 
weight 800mg are easy to handle. The following are examples of diluents used in tablet 
formulations .E.g. Lactose, lactose anhydrous, lactose spray dried, direct compressible 
starch, hydrolyzed starch, MCC, other cellulose derivatives, dibasic calcium phosphate 
dihydrate, mannitol, sorbitol, sucrose, calcium sulphate dehydrate, dextrose, etc
7
. 
Binders
8 
These are the dry powders or liquid which are added during wet granulation to 
promote granules or to promote cohesive compact during direct compression. They provides 
mechanical strength to the tablets. Binders can be in powder form and liquid form. Examples 
of the binders are  
1. Powder binders: Methyl cellulose, polyvinyl pyrolidone, PEG. 
2. Solution binders: Gelatin, PVP, HPMC, PEG, sucrose, starch. 
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Disintegrants
 
Disintegrants are added to the formulation as it breaks the dosage form into smaller 
particles when it comes in contact with the liquid. These smaller fragments have greater 
surface area which will increase the dissolution of the drug. When the tablet comes in 
contact with the liquid, the liquid penetrates into the pores of the tablets and breaks it into 
fragments. To improve the water uptake into the pores, certain hydrophilic polymers are 
added to the formulation
9
. E.g. starch, starch derivatives, clay, cellulose, alginates, polyvinyl 
pyrolidone, cross linked sodium carboxy methyl cellulose, etc. 
 
Lubricants
 
Lubricants are used to reduce the friction between the tablets and die cavity when the 
tablet is getting ejected from the die. Lack of lubricant can lead to problems like capping, 
scratch on the sides of the tablet, fragmentation of the tablet, shape out etc. For a lubricant 
the time of addition, concentration in which it is to be added and the combination are the 
important parameters. E.g. stearic acid, stearic acid salts, stearic acid derivatives, talc, PEG, 
surfactants, waxes, calcium stearate and magnesium stearate are the most commonly used 
lubricants
10
. 
 
Glidants
 
Glidants are used to improve the flow property of the formulation. It reduces the 
friction between the particles and between the hopper and particles and die cavity and 
particles. Actually glidant, lubricant and anti-adherent have a close relation to each other. 
They have some functions in common. Most of the glidants used are hydrophobic, thus they 
are to be carefully added (i.e) concentration regulated. E.g. talc, colloidal silicone dioxide, 
corn starch. 
 
Anti-Adherents 
Anti-Adherents are added to prevent adhesion of tablet material to the punches and dies.  
E.g. Talc, magnesium stearate, starch. 
Miscellaneous 
Apart from the above mentioned principal ingredients, the following excipients also 
improve the dosage form characters. They are adsorbents, flavoring agents, colouring agents 
and sweetening agents. 
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Adsorbents 
Adsorbents are used when there is a need to add a liquid or semisolid ingredient in 
the formulation. Adsorbents are capable of sorbing the liquid component on to the dry 
powder. Thus oil or liquid component can be incorporated into the powder. E.g.Magnesium 
oxide, kaolin,bentonite,etc. 
 
Flavoring agents 
They are incorporated into the formulation to improve the flavor or to give a pleasant 
taste to the formulation. Flavoring agents are mostly restricted to the formulations in which 
are intended to be released in the mouth or chewable tablets. They are usually added in along 
with the granules .E.g. Chocolate flavor, peppermint flavor, vanilla flavor, Trusil orange 
flavor etc. 
 
Coloring agents 
 Colorants are added to the formulation in order to increase the appeal, patient compliance 
or for identification of the formulation. Usually the colorants are added in the form of 
insoluble powder or in liquid form. E.g. FD&C and D&C dyes and lakes. 
 
Sweetening agents 
Sweetening agents are added to control the taste and hence the acceptability of tablets.        
These agents are of particular importance if the conventional tablet contains a bitter drug or, 
more importantly, if it is a chewable tablet. E.g.Aspartame, sucralose, sucrose, glycerin, 
mannitol, sorbitol, acesulfame potassium, saccharin sodium etc. 
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1.3. DIFFERENT TYPES OF TABLETS11 
Tablets are solid dosage form manufactured either by dry granulation, wet granulation or 
direct compression containing medicaments with or without excipients, intended to produce 
desired pharmacological response. Various types of tablets are being manufactured 
according to the route of administration and type of dosage form. They are 
Tablets ingested orally includes  
1.  Sugar coated tablet  
2. Chewable tablet 
3. Film coated tablet 
4. Compressed tablet  
5. Multiple compressed tablet  
6. Enteric coated tablets 
 Sugar coated tablets: 
These are compressed tablets which are coated with sugar, in order to mask the bitter 
taste or odor of the drug. 
Chewable tablets: 
These are big sized tablets which are difficult to swallow. Hence they are made in 
such a way that they are consumed by chewing the tablet. Most of antacid tablets are 
chewable types. 
 Film coated tablets: 
These are compressed tablets covered with a thin layer or film of a water soluble 
material. A number of polymeric substances may be used for film coating. Film coating 
imparts the same general characteristics as sugar coating, in addition it offers reduced time 
period required for the coating operation
12
. 
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Compressed tablets: 
These tablets are prepared by compression technique in which tablets are not coated 
with any material. It comprises a mixture of active substances and excipients usually in 
powder form, pressed or compacted into a solid dose
13
. 
Multiple compressed tablets: 
These tablets are prepared to separate physically or chemically incompatible 
ingredients or to produce repeat action or prolonged action products. A special type of tablet 
making machine is used which provides compressions.  
Enteric coated tablets:  
These are compressed tablets which are coated with substance which disintegrates in 
intestine. A tablet that has special outer covering designed to dissolve in the small intestine. 
Once the enteric coating is dissolved, the tablet disintegrates and the active ingredient gets 
absorbed in the systemic circulation. 
Tablets used in oral cavity includes
 
 1. Sublingual tablets 
2. Buccal tablets 
Buccal tablets and Sublingual tablets: 
These are small flat oval tablets, intended to be dissolved in the buccal pouch (buccal 
tablets) or beneath the tongue (sublingual tablets) for absorption through the oral mucosa
14
. 
Tablets used to prepare solution includes  
1. Effervescent tablets 
2. Molded tablets 
2. Dispensing tablets 
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Effervescent tablets:  
They contain sodium bicarbonate and an organic acid such as tartaric or citric acid 
along with the drug. In the presence of water, they react liberating carbon dioxide which acts 
as a distintegrator and thus produces effervescence.  
Molded tablets:  
Tablet Triturates are molded tablets made of powders created by moistening the 
powder mixture with alcohol and water. They are used for compounding potent drugs. 
Dispensing tablets:  
These tablets contain excipients which gets dissolved quickly to form a clear 
solution. These tablets are highly toxic if taken orally by mistake. The medicaments 
commonly incorporated in these tablets include mild silver proteinate, bichlorides of 
mercury merbromin and quaternary ammonium compounds. 
Tablets which are administered via other route includes:  
1. Vaginal tablet 
2. Implantation tablets 
Vaginal tablets: 
These tablets are meant to dissolve slowly in the vaginal cavity. The tablets are 
typically ovoid or pear shaped to facilitate retention in the vagina. These tablets are used to 
release steroids, antibacterial agents or astringents to treat several vaginal infections. 
Implantation tablets: 
These are the tablets meant to be put in the body sub-surfaces mostly below the skin or 
into muscles. These implants once inserted into the body tissues, they release the drug 
slowly over a period of months to year. Drugs like contraceptives, steroids are given in this 
route. There is no need for regular administration of the drug if these implants are used. But 
they can cause pain and sometimes release excess drug leading to toxicity
15
. 
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1.4. MANUFACTURING PROCESS OF TABLETS16 
The typical manufacturing process of tablets are given in table.1 
Table: 1. Typical Unit Operation Involved In Wet Granulation, Dry Granulation and 
Direct Compression methods. 
Wet granulation Dry granulation Direct compression 
1.Milling and mixing of drugs  
and excipients 
1.Milling and mixing of drugs  
and excipients 
1.Milling and mixing of 
drugs  and excipients 
2.Preparation of binder solution 2.Compression into slugs 
2.Compression of tablet 
3.Wet massing by addition of 
binder solution or granulating 
solvent 
3.Milling and screening of 
slugs _ 
4.Screening of wet mass 4.Mixing with lubricant and  
disintegrant _ 
5.Drying of the wet granules 5.Compression of tablet 
_ 
6.Screening of dry granules 
_ _ 
7.Blending with lubricant and 
disintegrants _ _ 
8.Compression of tablet 
_ _ 
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1.5. TABLET COATING 
Tablet coating can be described as a process of applying an edible paint on the surface of 
a pharmaceutical dosage form to achieve specific benefits. This is an additional process in 
tableting which causes an increase in the cost of tablet production. Coating can be applied to 
several kinds of solid dosage forms like tablets, pellets, pills, drug crystal, etc. When a 
coating solution is applied to a batch of tablets in a coating pan, the surfaces of the tablet get 
covered with a tacky polymeric film. The tablets are then allowed to dry and the film 
eventually forms a non-sticky dry surface. The coating technique involves parameters such 
as the spray pattern, drop size and nozzle spacing (in addition to multiple other non-spray 
related parameters) which must all be precisely controlled in order to ensure uniform 
distribution of the coating material. 
 
1.5.1.Objectives of Tablet Coating 
1. To mask the disagreeable odor, color or taste of the tablet. 
2. To offer a physical and or chemical protection to the drug. 
3. To control and sustain the release of the drug from the dosage form. 
4. To incorporate another drug which create incompatibility problems. 
5. To protect an acid-labile drug from the gastric environment. 
6. To increase the mechanical strength of the dosage form. 
 
In a coating process, it is most desirable that the coating should be uniform and should 
not crack under stress. Hence, various techniques were designed for the application of the 
coating on the tablet surface. Generally, the coating solution are sprayed onto the uncoated 
tablets as the tablets are being agitated in a pan, fluid bed, etc. As the solution is being 
applied, a thin film is formed which sticks into each tablets. The liquid portion of the coating 
solution is then evaporated by passing hot air over the surface of the tumbling pans
17
.  
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1.5.2.Advantages of Tablet Coating 
1. Tablet coating must be stable and strong enough to survive the handling of the tablet, 
must not make tablets stick together during the coating process and must follow the 
fine contours of embossed characters or logos on tablets.  
2. Coating is necessary for tablets that have an unpleasant taste and a smoother finish 
makes large tablets easier to swallow. 
3. Coating provides physical and chemical protection, protects the drug in the stomach 
and control its release profile. 
4. The colorful tablets can also be prepared by the use of dye in the coating solution 
5. Drugs that are sensitive to oxygen may require coating18. 
 
1.5.3.Disadvantages of Tablet Coating 
1. The uneven coat may produce rough surface of the tablet.  
2. The coating solutions used to coat the tablet may be toxic in nature. 
3. The coating may increase the bulk and weight of the tablet. 
4. Relatively high cost19. 
 
1.5.4.Basic Principles Involved in Tablet Coating 
Tablet coating is the application of coating composition to moving bed of tablets with 
concurrent use of hot air to facilitate evaporation of solvent.  
1. Coating solution which influences the release pattern as little as possible and does not 
markedly change the appearance. 
2.  Color coating which provides insulation. 
3. To incorporate another drug or formula adjuvant in the coating to avoid chemical 
incompatibilities or to provide sequential drug release. 
4. To improve the pharmaceutical elegance by use of special colors and contrasting 
printing
20
. 
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1.6. COATING PROCESS DESIGN AND CONTROL  
In most coating methods, when the tablets are being agitated in a pan, fluid bed, etc. 
spraying of coating solution on tablets takes place. As the solution is being sprayed, a thin 
film is formed that adheres directly to each tablet. The coating may either be formed by a 
single application or may be built up in layers through the use of multiple spraying cycles. 
Firstly, uncoated tablets are placed in the pan, which is typically tilted at an angle from the 
horizontal, and then the liquid coating solution is introduced into the pan while the tablets 
are tumbling.  By passing hot air over the surface of the tumbling tablets, the liquid portion 
of the coating solution is then evaporated. In comparison, a fluid bed coater operates by 
passing hot air through a bed of tablets at a velocity sufficient to support and separate the 
tablets as individual units. Once separation takes place, then the tablets are sprayed with the 
coating composition  
 
The coating process is usually a batch operating task consisting of the following phases:  
 Identification of batch and Recipe selection (film or sugar coating) 
 Loading/Dispensing (accurate dosing of all required raw materials) 
 Warming 
 Spraying (Both application and rolling are carried out simultaneously)  
 Drying 
 Cooling 
 Unloading 
 
1.6.1.Coating Equipment 
A modern tablet coating system combines several components such as
21
:  
 A coating pan. 
 A spraying system.  
 An air handling unit.  
 A dust collector. 
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1.6.2.Tablet Coating Defects: 
 Sticking and picking 
 Roughness 
 Orange peel effect 
 Bridging and filling 
 Blistering 
 Hazing / Dull film  
 Color variation 
 Cracking  
  
Sticking and Picking: 
Over wetting or excessive film tackiness causes tablets to stick to each other or to the 
coating pan. On drying, at the point of contact, a piece of the film may remain adhered to the 
pan or to another tablet, giving a “picked” appearance to the tablet surface and resulting in a 
small exposed area of the core. It is caused by over-wetting of the tablets or under-drying or 
by poor tablet quality. 
  
Roughness: 
A rough or gritty surface is a defect often observed when the coating is applied as a 
spray. Some of the droplets may dry rapidly before reaching the tablet bed, resulting in 
deposits of spray dried particles on the tablet surface. Moving the nozzle closer to the tablet 
bed or reducing the degree of atomization can decrease the roughness due to spray drying. 
Roughness also increase with pigment concentration and polymer concentration in the 
coating solution. 
 
Orange Peel Effect: 
Inadequate spreading of the coating solution before drying causes a bumpy or orange 
peel effect on the coating. This indicates that spreading is impeded by too rapid drying or by 
high solution viscosity. Thinning the solution with additional solvent may correct this 
problem. 
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Bridging and Filling: 
During drying, the film may shrink and pull away from the sharp corners of 
intagliation or bisect resulting in a bridging of the surface. Filling is caused by applying too 
much solution, resulting in a thick film that fills and narrows the monogram or bisect. 
 
Blistering:  
When coated tablets require further drying in oven, too rapid evaporation of the 
solvent from the core and the effect of high temperature on the strength, elasticity and 
adhesion of the film may result in blistering. 
 
Hazing / Dull Film: 
It is also called as “Bloom.” It can occur when too high processing temperature is 
used for a particular formulation. It can also occur if the coated tablets are exposed to high 
humidity conditions and partial salvation of film results.  
 
Color Variation: 
This problem can be caused by processed conditions or the formulation. Improper 
mixing, un even spray pattern and insufficient coating may result in color variation. 
Migration of soluble dyes, plasticizers and other additives during drying may give the 
coating a mottled or spotted appearance.  
 
Cracking: 
It occurs if internal stresses in the film exceed the tensile strength of the film. The tensile 
strength of the film can be increased by using higher molecular weight polymers or polymer 
blends. Internal stresses in the film can be minimized by adjusting the plasticizer type and 
concentration and the pigment type and concentration
22
. 
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1.7. ENTERIC COATING 
An enteric coating is a barrier that controls the location of oral medication in the 
digestive system where it is absorbed. The word “enteric” indicates small intestine. 
Therefore enteric coatings will prevent the release of medication before it reaches the small 
intestine. The enteric coated polymers remain unionise at low pH and therefore remain 
insoluble. But as the pH increases in the GIT, the acidic functional group capable of 
ionisation and the polymer swells or becomes soluble in the intestinal fluid. Materials used 
for enteric coating includes E.g. Cellulose acetate phthalate (CAP), Cellulose acetate 
trimellitate (CAT), Polyvinyl acetate phthalate  (PVAP), Hydroxy propyl methylcellulose 
phthalate (HPMCP), fatty acids, waxes, shellac and plant fibres. An ideal enteric polymer 
will;
 
 Protect drug from being destroyed by gastric contents, either enzymes or highly 
acidic gastric fluids. E.g. Low pH destroys some drugs (Erythromycin). 
 Prevent or reduce nausea and vomiting associated with a drug’s irritation of gastric      
mucosa. E.g. Aspirin. 
 Deliver the drug to its absorption site in the intestine. 
 Deliver the drug intended for local action in the intestine. E.g. Intestinal 
antibacterial or antiseptic agent. 
 Minimize first pass metabolism23. 
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1.7.1. Advantages of Enteric Coated Tablets 
1. Enteric coating is employed for a number of therapeutic, safety and medical reasons. 
(E.g) Some drugs when directly exposed to the gastric mucosa, including aspirin and 
vigorous electrolytes such as NH4Cl produce gastric irritation. 
2.  The low pH of the stomach may destroy some drugs and hence enteric coating may 
deliver the drugs in highest concentration possible within the intestine. 
(E.g) Anthelmintic drugs. 
3. Protect the active pharmaceutical ingredients, from the acidic environment of the 
stomach (E.g. Enzymes and certain antibiotics). 
4. Minimize first pass metabolism of drugs
24
. 
 
1.7.2.Disadvantages of Enteric Coated Tablets 
 1. Relatively high cost, long acting time and high bulk led to the use of other coating 
materials. 
2. This process is tedious and time consumed and it requires the expertise of highly 
skilled technician
25
.  
  
1.7.3.Enteric Coating – Imperative: 
When a tablet is swallowed it travels down the oesophagus to the stomach. In the 
stomach the tablet is churned and gyrated in highly acidic digestive secretions with pH (1- 4) 
for 45 min to 2 hours.  If anything left of tablet, it will be passed through the duodenum to 
the small intestine. Stomach acid breaks down the tablets to prematurely release active 
ingredients (i. e) enzymes. The highly acidic environment of the stomach destroys the 
majority of the enzymes activities. The enteric coating was done on different types of dosage 
forms like tablets, capsules, pellets and granules as these are most commonly used when 
compared to other dosage forms.
26
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1.8. COMPOSITION OF ENTERIC COATED TABLETS 
An enteric coating composition includes 0.01% - 10% resin and about 0.01% - 10% 
polymer. The enteric coating composition may be applied to a substrate, such as 
pharmaceutical, neutraceutical, fruit, vegetable, agriculture or industrial product to form an 
enteric coating on the substrate. After the forming of tablet core, the tablet core are first 
coated with separating layer and then with the enteric coating layer. The Enteric coated 
formulation usually contains the following components
27 
 
a) Polymer.  
b) Plasticizer.  
c) Solvent. 
d) Colorant  
 
a) Polymer 
Polymers are substance containing a large number of structural units joined by the 
same type of linkage. These substances often form into a chain-like structure. Starch, 
cellulose and rubber all possess, polymeric properties. Enteric coating polymers with an 
acid-resistant property generally possess free carboxylic acid groups on the polymer 
backbone. They are insoluble in acidic media but become deprotonated and dissolved in 
basic media at pH nearly neutral values (pH>5). 
 E.g.Alginate, Polyvinyl acetate phthalate (PVAP), Methacrylic acid copolymer dispersion 
(Eudragit L30D-55). 
 
b) Plasticizer 
Success of enteric coating efficiency mostly relies on the addition of plasticizer. 
Plasticizers are a group of auxiliary components that improve elasticity of the polymeric 
film. The type of plasticizer should be selected carefully as it influences the film brittleness, 
compatibility with the coating substrates and product stability. A wide range of plasticizers 
are available to the formulator such as phthalate esters, phosphate esters, other esters like 
citrates, stearates, sebacate, oleate, adipate etc. E.g. Tri ethyl citrate, PEG (Polyethylene 
Glycol), TEC (Triethyl Citrate). 
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c) Solvent 
Solvents are used to dissolve or disperse the polymers and other additives and 
convey them to substrate surface. Generally enteric coating polymers dissolve well in 
organic solvents, giving stable coating solution that facilitates faster coating processes due to 
easy evaporation of organic solvents. The solvents used in enteric coating process are listed 
below 
1. Water.  
2. Alcohols.  
3. Ketones.  
4. Esters.  
5. Chlorinated Hydrocarbons.  
 
d) Colorant 
Colorants are mainly used to impart a distinctive appearance to the pharmaceutical 
dosage forms. There are many types of pharmaceutical formulations which need to be 
colored such as tablets, tablets coatings, capsules (hard gelatin, soft gelatin), liquid orals, 
tooth pastes, ointments and salves etc. The purpose of coloring varies with different 
formulations. Coloring may be required to increase the aesthetic appearance or to prolong 
the stability or to produce standard preparations or for identifications of a particular 
formulation. The commonly used colorants in coating are water soluble dyes. However, the 
overall colour effect of these dyes depend on the dye concentration at a particular point, 
thickness of film at that point and the residual moisture content in the film at that point.    
E.g. FD and C lakh yellow NO-5. 
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1.9. EVALUATION OF ENTERIC COATED TABLETS: 
Tablets when formulated may undergo physical and chemical changes, which may alter 
their bioavailability. Therefore, the tablets are to be evaluated before dispensing to ensure 
their stability and bioavailability throughout their shelf life. The precompression parameters 
evaluated during tableting are outlined below
28
.  
 
Pre-compression Parameters 
 
 Loss on drying 
 Bulk density 
 Tapped density 
 Carr’s index 
 Hausner’s ratio 
 
Evaluation of enteric coated tablets are outlined below 
 
Evaluation of Tablets 
 Tablet appearance 
 Hardness test 
 Thickness test 
 Weight variation test 
 Disintegration test 
 Drug content 
 In vitro dissolution test 
 Stability studies 
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   CHAPTER-2  
REVIEW OF LITERATURE 
 
Naresh et al., (2015)
29 
formulated enteric coated tablets of Duloxetine hydrochloride by  
direct compression technique using polymer hydroxy propyl methylcellulose phthalate, 
sodium starch glycolate and other excipients like talc, calcium phosphate, magnesium 
stearate. Hydroxy propyl methylcellulose phthalate was used for preventing drug release in 
stomach. Sodium starch glycolate was used to reduce the disintegration time of tablet in 
intestine.  Press coated tablets were prepared with different concentrations of enteric coated 
material like hydroxy propyl methylcellulose phthalate. Press coated tablets were evaluated in 
terms of their pre compression parameters, physical characteristics, weight variation, 
hardness, drug content and further tablets were evaluated for in vitro drug release. In the 
dissolution study no drug release was observed in formulation F30 and F31 in acidic medium 
at first 2 hrs. Gradually drug release was increased in alkaline medium. Hence it can be 
concluded that enteric coated tablets by press coating technology can be prepared by using 
different concentrations of HPMCP to reduce the gastrointestinal tract side effects. 
 
V Rajitha et al., (2017)
30
 formulated and evaluated Duloxetine hydrochloride tablets by 
using  different enteric polymers like Acryl EZE, HPMC phthalate HP 55, HPMC phthalate 
HP 55 S, HPMC phthalate HP 50. The prepared tablets were evaluated for various post 
compression parameters. With Acryl EZE only 5% drug release was observed in pH 5.5 
phosphate buffer even after 90 minutes. The Enteric coating suspension was very viscous and 
the process was very slow when HPMC phthalate HP 55 S was used as enteric polymer. 
HPMC Phthalate (HP 55) showed poor drug release in pH 5.5 phosphate buffer, whereas the 
drug release pattern with HPMC phthalate HP 50 was high when compared to innovator. So a 
combination of HPMC Phthalate (HP 55) and HPMC Phthalate (HP 50) were used and 
different ratios of HPMC Phthalate (HP 55) and HPMC Phthalate (HP 50) were tried out. The 
release profile of E12 formulation matched with that of the innovator product (HP 55: HP 
50=6:4). Different solvent systems like IPA/DCM-1:1, Acetone/water in the ratio 1:1 and 8:2 
were tried out as enteric solvents. Acetone/water in the ratio 8:2 was optimized. The Different 
kinetic models were applied to optimize enteric coated formulation (E12) and observed that it 
follows zero order kinetics with Higuchi diffusion mechanism. The stability studies were 
conducted at 40ºC/75%RH (accelerated stability testing) for 2 months. The overall results 
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revealed that the assay, acid resistance, dissolution release profile of optimized enteric coated 
formulation (E12) complies with that of innovator product and was found to be stable. 
 
P.Rajesh et al., (2013)
31
 formulated   Duloxetine delayed release (DR) pellets. Duloxetine is 
a novel anti-depressant drug used widely for treatment of depression and generalised anxiety 
disorder, but it is having disadvantage of forming a toxic product of alpha-naphthol when 
comes in contact with 0.1N HCl. So in order to prevent toxic product formation and to 
promote the enteric release, the present research work was directed towards the development 
of a delayed release dosage form of Duloxetine in the form of capsules. In the present study 
polymers such as HPMC E5, HPMC HP 55 was used as coating polymers which helps in 
providing delayed release. The di ssolution studies of the dosage form was performed and 
analysed by HPLC. Different evaluation parameters such as drug - excipient compatibility by 
FT-IR, XRD and DSC were done and in vitro drug release was performed which showed 
dissolution profile as per specification. Different polymers are optimized on the basis of 
release pattern. The marketed formulation was evaluated for the in vitro release studies and 
formulated product is compared with the marketed delayed release pellets. The study 
concluded that the Duloxetine delayed release formulation containing 10% HPMC E5 and 
15% HPMC HP 55 showed good release pattern and can be used for future research in 
developing enteric release capsule formulation for acid labile drugs. 
 
Preethi Mylavarapu et al., (2011)
32
 formulated Duloxetine hydrochloride delayed release 
enteric coated pellets in capsules. Since Duloxetine hydrochloride degrades in the acidic 
environment, it is important to bypass the acidic pH of the stomach. Protection of drug from 
acidic environment is done by coating the drug with enteric polymers by using suspension 
layering technique in Fluidized bed processor (FBP) with different enteric polymers like 
PVAP (Poly Vinyl Acetate Phthalate), Kollicoat MAE 30 DP, Eudragit L30 D55 
(Methacrylic acid copolymer) and HPMCP (Hydroxy propyl methyl cellulose phthalate). The 
prepared pellets were studied for their in vitro release studies and were analyzed by using 
HPLC technique. The release kinetics was analyzed using the zero-order model, first-order 
model and Higuchi’s square root equation. FT-IR (Infrared spectroscopy) and DSC 
(Differential Scanning Colorimetry) studies were performed to know the compatibility of the 
drug with various excipients and SEM (Scanning Electron Microscopy) analysis were 
performed to know the particle size and morphology of the pellet. The results depicted that 
HPMCP gave a good dissolution profile and process suitability compared to Eudragit L30 
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D55, Kollicoat MAE 30DP and PVAP and hence optimized based on the similarity factor (F2 
value). It can be concluded that the optimized formulation (E10) of Duloxetine 
Hydrochloride delayed release pellets in capsules was found to achieve the effective drug 
levels in the intestine. 
  
Sk Zakir Hussain et al., (2011)
33
 developed delayed release pellets of Duloxetine 
hydrochloride with a suitable polymer by using suspension layered method. Drug loaded 
nuclei was prepared using suspension layered technique in a Fluidized Bed Processor, the 
nuclei was coated with an acid resistant acrylic polymer (Eudragit L30-D55) and compared 
the acid resistant properties with HPMC phthalate. The entire coating process was performed 
in a Fluidized Bed Processor with different thickness. The in vitro dissolution studies were 
conducted in 0.1N HCl for 2 hours followed by phosphate buffer (pH 6.8) for 1 hour with 
USP dissolution tester (Type II). The results generated in this study showed that proper 
selection of polymer material based on their physicochemical properties as well as polymer 
load is important in designing delayed release pellets with best fit of dissolution profile. It 
may be concluded that the F8 formulation is selected as an optimized formulation compared 
to other formulations since, the drug release in 3.5 hour’s fulfills all the requirements of 
enteric coated pellets.  
 
Sudipta Das et al., (2008)
34
 developed Duloxetine hydrochloride enteric coated tablets using 
Hypromellose phthalate (HP-55) as enteric coated materials in various proportions. Three 
formulations were prepared and all of them had same amount of ingredients but only 
difference is in percentage of coating applied. FT-IR study revelead that there was no 
interference to the drug with excipients. In vitro evaluation were carried out by using USP 
dissolution testing apparatus. The prepared tablets and commercial tablet showed a fair 
uniformity of drug content of 99 to 101 %. Physical parameters were observed fairly good in 
the present study conforming to requirements. Average weight of tablet of all three 
formulations was found in the range of 129 to 136 mg. In the present study hardness of all 
tablet formulations was observed in the range of 6 to 8 kg/cm
2
. Thickness of all three tablet 
formulations were found in the range of 3. 11 to 3.17 mm. Friability for all the formulations 
in the study was in the range of 0.028 to 0.068%. In vitro release profile was done in            
0.1 N HCl for 2 h and then pH 6.8 phosphate buffer. The commercial tablet after 2 h of 
operation in 0.1 N HCl, followed by pH 6.8 phosphate buffer media showed 100 % release at 
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45 min. In formulation 1 (6% enteric coating), two out of six tablets failed in 0.1 N HCl 
media. In formulation 2 (8 % enteric coating), one tablet failed in 0.1 N HCl media and  in 
formulation 3 (10% enteric coating), all the six tablets  passed in 0.1 N HCl media and 
showed good release profile at 45 min in phosphate buffer. Hence formulation 3 (10% enteric 
coating) fulfilled all the criteria for enteric coated tablets. 
 
 Surya Bhan Singh Rathore et al., (2013)
35
 formulated enteric coated tablets of Ilaprazole to 
reduce the gastrointestinal tract side effects. Four formulations of core tablets were prepared 
and one which showed rapid disintegration (around three minutes) was selected for enteric 
coating. Enteric coat was optimized using two different polymers such as HPMCP 50 and 
Eudragit L 100 in different concentrations. The prepared tablets were evaluated in terms of 
their pre-compression parameters, physical characteristics and in vitro release study. 2.5% 
seal coating on core tablets was optimized and 9% enteric coating on seal coated tablets was 
performed using HPMC P 50 (60%), triethyl citrate (10%) and IPA: DCM (60:40) which 
gives the highest dissolution release profile and f2 value. The stability results revealed that 
there was no change in the formulation even after 1 month accelerated stability study. So, 
prepared delayed release tablet of proton pump inhibitor was stable. Hence it can be 
concluded that delayed release tablets of Ilaprazole could be successfully developed using 
HPMCP 50 as enteric polymer to reduce the GIT side effects. 
Srilakshmi N et al., (2015)
36
 formulated Metronidazole enteric coated tablets using various 
synthetic hydrophilic polymers to control the drug delivery and target the drug to the 
intestine. The aim of the study was to formulate core tablets using different polymers such as 
HPMC K 15M and HPMC K100M in different ratios and the core tablets were coated with an 
enteric polymer. The prepared tablets were evaluated for weight variation, hardness, 
friability, content uniformity and in vitro drug release study. The angle of repose values 
obtained for the formulations ranged from 25.48
0
 to 30.40
0
. The compressibility index values 
for the formulations ranged from 11.36 to 21.8%. The Hausner’s ratio values for the 
formulations ranged from 1.12 to 1.25. This indicates the powder blend has good flow 
property. The weight variation of the tablets was within the limits of 5%. The measured 
hardness of tablets in all batches was ranged from 6.0 – 6.2 kg/cm2. Friability values were 
found to be less than 1% in all prepared formulations and considered to be satisfactory. Drug 
content was in the range of 99.17 to 100.2 % indicating good content uniformity in the all 
formulations. Formulation F12 showed good controlled drug delivery, as it showed 96% drug 
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release for 24 hrs and it follows Korsmeyer-Peppas model along with non-Fickian diffusion 
mechanism. Thus, the formulated enteric coated tablets seem to be a potential candidate for 
targeted and sustained drug delivery of Metronidazole for the treatment of diseases in colon. 
  
Rabia Bushra et al., (2010)
37
 developed enteric coated Ibuprofen tablets to avoid gastric 
mucosal irritation and to let active ingredient to be absorbed easily in small intestine. The 
formulation was developed through the direct compression process. Enteric coating was done 
using an opadry white sub coating and an aqueous coating dispersion of Acryl-Eze. Enteric 
coated formulation was subjected to disintegration and dissolution tests by placing in 0.1 M 
hydrochloric acid for 2 h and then 1 h in phosphate buffer with a pH of 6.8. About 0.05% of 
drug was released in the acidic phase and 99.05% in the basic medium. Dissolution and 
disintegration results showed strong acid resistance whereas the drug was freely released in 
6.8 buffer solution. The results of stability testing were satisfactory, indicating that coated 
Ibuprofen tablets were stable under the testing conditions. These results reflect that Ibuprofen 
can be successfully enteric coated in order to prevent its release in the stomach and facilitate 
rapid release of the drug in the duodenum, due to the presence of super disintegrant.  
Malay R Patel et al., (2012)
38
 formulated Doxycycline hydrochloride delayed release tablets 
by dry mix method. This drug is universal antibiotic and can be targeted to the specific site of 
absorption by enteric coating using pH dependant polymers. Pre formulation studies like 
angle of repose, bulk density, tapped density, porosity, carr's index, hausner's ratio were 
performed. Enteric coating was carried out using different polymers like Eudragit L-30,      
D-55, hydroxy propyl methylcellulose phthalate, cellulose acetate phthalate and acryl-EZE. 
The prepared tablets were evaluated for hardness, friability, weight variation, drug content, 
disintegration and in vitro dissolution. Values for the angle of repose were found in the range 
of 22.1
0
 – 27.70. The prepared blends showed good flow properties. Hardness was found to 
be in the range of 7 to 11 (kg/cm
2
) in all the formulations indicating good mechanical 
strength. In all the formulations the friability value is less than 1% giving an indication that 
tablets formulated are mechanically stable. The percentage weight variation was within the 
limits. Drug content was found to be between 90% to 110% and it was within the limits. 
Formulation D5 and D8 remain intact in 0.1 N HCl and dissolved fastly in pH 6.8 phosphate 
buffer. Hence it can be concluded that the formulation D5 and D8 containing Eudragit L 30 
and D 55 showed better results compared to the formulation containing hypromellose 
phthalate and cellulose acetate phthalate.  
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Pranav Palshikar et al., (2013)
39
 developed enteric coated tablets of Sodium valproate using 
cellulose acetate phthalate as enteric coating material. Core tablets were prepared by non-
aqueous granulation method and seal coated with PVP K-30 which act as moisture barrier. 
This seal coated tablet was further coated with cellulose acetate phthalate to dissolve in the 
intestinal fluid. The in vitro release result showed that enteric coating was capable of 
restricting the drug release in the acidic media. The optimized batch was found to be capable 
of releasing the drug in same manner of a marketed formulation of Sodium valproate. Hence 
it can be concluded that, enteric coated Sodium valproate tablets can be prepared by non 
aqueous granulation method to release the drug in the intestine. 
Farha Amna Shaik et al., (2014)
40
 formulated Rabeprazole delayed release enteric tablets by 
direct compression method. Five formulations were developed by preparing core tablets using 
mannitol as diluent and crospovidone as super disintegrant in different proportions and varying 
the compositions of sub coating and enteric coating using opadry white and enteric yellow. In the 
pre formulation studies the micromeritic flow properties of the API were assessed by 
determining angle of repose, compressibility index and hausner’s ratio. The results indicated 
good free flow of Rabeprazole. Formulation F5 is considered as an efficient delayed release 
formulation of Rabeprazole as it was comparable to the innovator product. The developed 
delayed release tablet formulation is quite stable with regard to drug content, physical properties 
and dissolution rate in the accelerated stability testing.  Hence it can be concluded that enteric 
coated formulation F5 could be successfully prepared to achieve effective drug levels in the 
intestine. 
 
Sourav Tribedi et al., (2013)
41
 developed Pantoprazole sodium enteric coated tablets by 
direct compression method using different concentration of microcrystalline cellulose as 
filler, mannitol and dicalcium phosphate as diluents, croscarmellose sodium as disintegrating 
agent, magnesium stearate and talc as  glidant and lubricant respectively. The prepared tablets 
were evaluated for hardness, weight variation, friability and drug content uniformity and it 
was found that the results complied with official standards. The prepared tablets were coated 
using enteric coating polymer such as cellulose acetate phthalate, Eudragit L100 by dip 
coating method. The in vitro release was studied using acidic buffer pH 1.2 and phosphate 
buffer pH 6.8. Among all formulations C2F9 was found best, with hardness 6.3 ± 0.14 
(Kg/cm
2
), drug content 98.54 ± 0.12(%), disintegration time 6.02± 0.21(min) and percentage 
cumulative drug release which started after 120 min and reached 99.72% after 180 min. 
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Stability studies indicated that the developed tablets were stable and retained their 
pharmaceutical properties at room temperature and at 40 °C / 75% RH for a period of 3 
month.  
 
Madusudhan RaoYamsani et al., (2015)
42 
developed enteric coated sustain release tablets of 
Lansoprazole by using enteric polymers like Kollicoat MAE 30DP and Eudragit L 100. 
Primary characterization of the drug was done by performing the melting point, identification 
test by Fourier Transform Infrared Spectroscopy, solubility and assay. Using complexation 
technique different ratios of the drug were complexed with cyclodextrin to improve photo 
stability. The stability test results indicated that the inclusion complex was more stable than 
raw Lansoprazole in the light. It was observed that inclusion complex of Lansoprazole 
showed increased solubility by about 4.5 times. Among the four polymers chitosan, xanthum 
gum, locust bean gum and guar gum, chitosan was chosen for further coating process. 
Physico-chemical and in vitro drug release studies were performed for all the formulations. 
F4C formulation was found to be best formulation which showed better resistance in 0.1N 
HCl, sustained well and with in vitro release of 97.83± 0.39% release in 12h. The study 
concludes that Lansoprazole and β-CD complex improves the photostability of the enteric 
coated sustain release tablets of Lansoprazole. 
 
N. Damodharan et al., (2010)
43
 developed small intestine targeting tablets of Doxycycline 
hydrochloride by wet granulation method and enteric coating of tablets using pH dependent 
polymers like Eudragit and HPMC Phthalate. Pre formulation studies like angle of repose, 
bulk density, tapped density, porosity, carr's index and hausner's ratio were performed. Six 
batches (F1 to F6) were formulated and evaluated for hardness, friability, weight variation, 
drug content, disintegration and in vitro dissolution. The prepared blends showed good flow 
properties. Hardness was found to be in the range of 6‐8 (kg/cm2) in all the formulations 
indicating good mechanical strength. In all the formulations the friability value is less than 
1% giving an indication that tablets formulated are mechanically stable. The weight variation 
was found to be within the limits. Drug content was found to be between 90% to 110% and it 
was within the limits. It was observed that the drug release of DF1 (5% HPMC P‐55) showed 
better enteric release of 87% at the end of 90 min and DF4 (5% Eudragit L100) showed drug 
release of 94% at the end of 90 min. The study concluded that formulation DF4 could be 
successfully used to protect the drug release in the hostile environment of upper GIT. 
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 Prasanta Kumar Choudhury et al., (2012)
44
 formulated matrix tablets of Ornidazole by 
wet granulation method using matrix forming natural polymers like Guar gum and Xanthan 
gum in combination with different proportions. The further effect of enteric coat on the 
matrix tablets for colon specific drug release was investigated. The Ornidazole optimized 
matrix formulation OM1 showed drug release around 32.37±0.33% in 2 hrs. So it was further 
enteric coated with 5% Eudragit S100 and coded as OME1 which showed 44.09±0.16% of 
drug release after 12 hrs. All formulations were subjected to hardness test, friability test, 
determination of uniform diameter and thickness, drug content and in vitro release study.     
in vitro dissolution studies indicated that the drug release in upper part of GIT from matrix 
tablets of Ornidazole can be prevented by enteric coating with pH sensitive polymer 
(Eudragit S100), which releases the drug specifically in colonic region to achieve target 
delivery. Hence it can be concluded that guar gum, xanthan gum has the potentiality for colon 
specific drug delivery of Ornidazole and Eudragit S100 can be used to protect the drug 
release in the hostile environment of upper GIT.  
 
Mohammed Sarfaraz et al., (2014)
45
 formulated enteric coated tablets of Salbutamol 
sulphate immediate release tablets by direct compression method using superdisintegrants  
like croscarmellose sodium, crospovidone and sodium starch glycolate in different 
concentrations (2.5 - 7.5% w/w) to improve disintegration time. The formulation, which 
showed best disintegration and dissolution profile, was coated with ethyl cellulose as inner 
layer and Eudragit S100 as outer enteric coating polymer. The optimized enteric coated 
formulation E6 containing 2.5% w/w of Eudragit S 100 and 30% w/w of ethyl cellulose as 
coating system inhibited the release of the drug in 0.1 N HCl and where as 99.04% of drug  
released in the intestinal medium. Thus, dissolution profiles indicated that E6 tablet 
containing 2.5% w/w of Eudragit S100 and 30% w/w of ethyl cellulose may be better 
alternative in the treatment of nocturnal asthma which overcomes the problems of 
conventional forms. 
 
 Ramesh Pastham et al., (2017)
46
 formulated Zileuton tablets by employing compression 
coating technology. Initially the core tablets were prepared by 30% concentrations of        
superdisintegrants, the formulated core tablets were then coated with the polymers by using 
compression coating technology. All the core and press coated tablet formulations were 
subjected to various physical and chemical evaluation tests. The thickness, hardness and 
weight variation shown by all the tablet formulations were found within the official 
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pharmacopoeias limits. In vitro release of Zileuton core tablet formulation F1 showed faster 
drug release after 15 min.  Faster drug release can be correlated with the high disintegration 
and friability observed in this study. The enteric coated formulations C1, C3 showed 
maximum drug release after 4 hour. Time dependent pulsatile drug delivery system has been 
achieved from tablet of formulation C3, C6 and C9 with 95.5%, 94.76% and 97.48% 
respectively. Hence it can be concluded that the in vitro drug release of the optimized 
formulations is suitable for pulsatile drug delivery. 
 
Anroop B Nair et al., (2010)
47
 formulated enteric coated tablets of Esomeprazole 
magnesium tri hydrate. Different core tablets were prepared and formulation (F-1) was 
selected for further enteric coating, based on the disintegration time. Seal coating was applied 
to achieve 3% weight gain using opadry. Enteric coating was carried out using different 
polymers like Eudragit L-30 D-55, hydroxy propyl methylcellulose phthalate, cellulose 
acetate phthalate and Acryl-EZE to achieve 5% weight gain. Disintegration studies showed 
that the formulations failed in 0.1N HCl media. Hence the quantity of enteric coating was 
increased to 8% w/w. In vitro analysis of the developed tablets was carried out. Results from 
disintegration time and dissolution rate studies indicate that all the Esomeprazole enteric 
tablets prepared possess good integrity, desirable for enteric coated tablets. Among the 
polymers studied, the methacrylic polymers exhibited better dissolution rate than the 
cellulose polymers. Stability studies indicate that the prepared formulations were stable for a 
period of three months when stored at 40°C ± 2°C / 75% ± 5% RH. This study concluded 
that enteric coated tablets of Esomeprazole can be prepared using any of the enteric coating 
polymer studied using a minimal weight gain of 8%. 
 
Deepak Kashyap et al., (2012)
48
 developed enteric coated Ibuprofen tablets using PVPK-30 
and starch as disintegrating agent. Methacrylic acid copolymer was used as an enteric coating 
material. The tablets were formulated using wet granulation method. Further in vitro drug 
release from Ibuprofen enteric coated tablets were studied using different percentage of 
coating material utilizing different dissolution mediums. Moreover, to achieve the maximum 
drug release, coating of 7% is desired. Hence it can be concluded that Ibuprofen enteric 
coated tablets prepared by wet granulation techniques, showed promising results.   
Methacrylic acid copolymer prevents the release of drug for the first 2hrs. The enteric coated 
tablets are economical and exhibit predictable release behavior. Moreover, with the specified 
percentage of coating material of 7% maximum release can be effectively achieved. The 
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coating with copolymer and non selective COX inhibitor properties makes the formulation an 
excellent candidate for colon specific drug delivery. The results suggested that the prepared 
enteric coated tablet is an excellent candidate for colon specific drug delivery. 
 
V Kalvimoorthi et al., (2011)
49
 formulated Aspirin delayed release tablets to understand the 
kinetics of drug release by applying mathematical and model-dependent approaches. Six 
formulations of delayed release tablets were prepared by the direct compression method and 
simple pan coating using Drug coat N-100 and hydroxy propyl methyl cellulose phthalate 
(HPMCP) as enteric coating polymers. The in vitro drug release was studied in pH 1.2 HCl 
and 6.8 pH phosphate buffer using USP dissolution apparatus Type 2 at 100 rpm.                       
Zero-order, first- order, higuchi and korsmeyer models were used to estimate the kinetics of 
drug release. The criteria for selecting the most appropriate model were based on the 
goodness of fit test and lowest sum of squares residual.  Hardness was found to be in the 
range of 6-8 kg/cm
2
 in all the formulations indicating good mechanical strength. In all the 
formulations the friability value is less than 1% giving an indication that tablets formulated 
are mechanically stable. Drug content was found to be between 90% to 110% and it was 
within the limits. The dissolution of F1, F2, F3, F4, F5 and F6 showed percentage drug 
release of 63.33%, 69.15%, 74.43%, 84.23%, 79.72% and 75.76% respectively at the end of 
45 min in the phosphate buffer.  Drug release from the optimal batch was explained by the 
Higuchi model. The difference in percent cumulative drug release of each point was highest 
for the optimum batch. F4 batch was considered to be the best enteric formula as it showed 
84.23% drug release at end of 45 min in the phosphate buffer. 
 
 Ajit Patil et al., (2011)50 formulated enteric coated tablets of Azithromycin dihydrate to 
reduce the gastro intestinal tract side effects. Three formulations of core tablets were prepared 
and one showed rapid disintegration (below three minutes) was selected for enteric coating. 
Enteric coat was employed by using different polymers such as HPMC-55, Eudragit, Ethyl 
cellulose in different ratios. Combination of HPMC-55 and ethyl cellulose (10:1.5) exibited 
better dissolution, disintegration, hardness and friability properties. This combination  
remained  intact for two hours in the acidic pH 0.1 N HCl and disintegrated completely in the 
phosphate buffer pH6.8 within half an hour. Combination of HPMC - 55 and the          
eudragit (10:1.5) was not intact more than one and half hour in the 0.1 N HCl, also      
HPMC-55 (F1)  not remain intact in 0.1N HCl for more than one hour. So, the combination 
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of HPMC -55 and ethylcellulose (F2) (10:1.5) was best for the enteric coating, which have 
given hardness (4-5kg/cm
2
), friability (0.8-1%), weight variation (490±10), content 
uniformity, percent drug release and disintegration  within officially specified limits. This 
study concluded that enteric coated tablets of Azithromycin dihydrate can be prepared by 
using combination of polymers studied to reduce the GI tract side effects. 
 
Deepak Kaushik et al., (2016)
51
 formulated enteric coated tablets of Benzimidazole 
derivative to enhance its stability. The tablets were coated with HPMC phthalate based 
enteric polymer with different amount of plasticizers and talc. Prior to enteric coating, core 
tablets were seal coated to prevent interaction between core and enteric layer. The core 
tablets were separated into three groups and seal coated with a colour coding scheme to 
coverage levels of 2% (white colour), 2.5% (yellow colour), 3% (orange colour) weight 
gains. The purpose of colour coding was to carry out the coating simultaneously to reduce the 
number of experiments and eliminate potential differences that may exist during separate 
coating processes. During each enteric coating process, a predetermined amount of labeled 
tablets were removed after attaining 6, 8 and 10% weight gains. Dissolution results revealed 
that all enteric coated formulations inhibited drug release for 2 h in 0.1 N HCl and drug 
release at most intermediate sampling time points in phosphate buffer, pH 6.8. Hence it can 
be concluded that the enteric coated tablets of proton pump inhibitor coated using polymeric 
dispersion of HPMC phthalate enhance the stability of drug by remaining intact in 0.1N HCl 
buffer. 
 
Vaishali Thakkar et al., (2012)
52 developed enteric coated tablets of Fluoxetine HCl by 
direct compression method and prepared nine batches using fenugreek mucilage at 40%, 50% 
and 60% concentration, HPMC at 10%, 15% and 20%; compritol ATO 888 at 10%, 15% and 
20% and ethyl cellulose at 2%, 3% and 4% concentration. Fenugreek mucilage was extracted 
from dried ripe seeds of Trigonella foenum-graecum (Fabaceae). Cellulose acetate phthalate 
was used as an enteric coating agent. The tablets were characterized for weight variation, 
crushing strength, friability, drug content and in vitro drug release study. All the          
formulations complied with standard specifications. The drug excipients compatibility study 
was performed by DSC and IR Spectroscopy and no incompatibility was found. The results 
of in vitro dissolution studies indicated that formulations X2, X5 and X8 released 7.03%, 
7.03%, 4.75% of Fluoxetine respectively at the end of 2 hour and 98.17%, 78.12%, 65.45% 
of Fluoxetine respectively at the end of 24 hour. Drug release rate was increased in polymer 
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order HPMC K 100M > ethyl cellulose > compritol ATO 888. Formulation X2 (50% 
fenugreek mucilage and 15% HPMC K 100M) could extend drug release upto 24 hour and it 
exhibited satisfactory drug release within first 2 hours and total release pattern was very close 
to marketed product. The mechanism of drug release was found to be diffusion coupled with 
erosion. Optimized formulation was found to be stable when exposed to 40
0
C/75% RH.  
Hence the study concluded that the optimized formulation containing 50% fenugreek 
mucilage and 15% HPMC K 100M was found to be stable at all the stability conditions  and 
exhibited drug release profile similar to marketed product. 
 Gobinath T et al., (2014)
53
 formulated Pantoprazole sodium enteric coated tablets by direct 
compression method using different concentration of microcrystalline cellulose as filler, 
mannitol and di calcium phosphate as diluents, croscarmellose sodium as disintegrating 
agent, magnesium stearate and talc as glidant and lubricant respectively. The prepared tablets 
were evaluated for hardness, weight variation, friability and drug content uniformity and it 
was found that the results comply with official standards. The prepared tablets were coated 
using enteric coating polymer such as cellulose acetate phthalate, Eudragit L100 by dip 
coating method. The in vitro release was studied using acidic buffer pH 1.2 and phosphate 
buffer pH 6.8. Stability studies indicated that the developed tablets were stable and retained 
their pharmaceutical properties at room temperature and 40 °C / 75% RH for a period of 3 
month. Among all batches C2F9 was found best, with hardness 5.60 ± 0.24 (Kg/cm
2
), drug 
content 99.08 ± 0.35(%), disintegration time7.02 ± 0.21(min) and percentage cumulative drug 
release which started after 120 min and reached 99.72 % after 180 min. 
 
Sachin D Bali et al., (2013)54 developed delayed release enteric coated tablets of 
Sulfasalazine using different enteric coat polymer to increase bioavailability and to prevent 
acid degradation, delivering the drugs to its local site of action in the intestine. Core tablets of 
Sulfasalazine were prepared and evaluated. The cellulose acetate phthalate, HPMC-P 
polymers were used to coat the core tablet. On the basis of weight gain and USP specification 
the tablets were coated. The design of enteric coating based on the transit time required for 
passage to the intestine may be accomplished through coatings of sufficient thickness. The 
formulation with 6% weight gain was selected as optimized batch which released 98.40% 
drug in pH 7.5 phosphate buffer. It is concluded that, the enteric coat polymer gives 
promising dosage form to target the organ and prevent the loss of Sulfasalazine. Hence it can 
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be concluded that the combination of CAP and HPMC-P have promising delay release 
property and can achieve higher bioavailability of Sulfasalazine. 
 
Vivek P Chavda et al., (2015)
55 
formulated enteric coated Paracetamol tablets to protect the 
drug from being released in stomach. Core tablets were prepared with and without 
superdisintegrant using wet granulation method. Dip coating method is used for coating were 
different concentration of Eudragit L100 is used as coating agent. Preformulation studies like 
angle of repose, bulk density, tapped density, porosity, carr's index, hausner's ratio were 
performed. The FDT2 batch showed the highest drug release at the end of total 135 min of 
94.13 % which are the satisfactorily promising results. So, we can conclude that the FDT2 is 
the optimized batch among all three batches. From the reproducible results obtained from the 
executed experiments it can be concluded that Eudragit L 100 can be used as enteric coated 
polymer. These results reflected that Paracetamol tablets can be successfully enteric coated in 
order to prevent its release in the stomach and facilitate rapid release of the drug in the 
duodenum, due to the presence of superdisintegrant.  
 
Roy Chowdhury Santanu et al., (2014)
56
 formulated enteric coated tablets of Erythromycin     
stearate by wet granulation method. Enteric coating of Erythromycin stearate tablets were 
done using two polymers like ethyl cellulose and pectin by multivariate ANOVA method by 
alternating the 2 variables X and Yin rows and columns. Polyethylene glycol was used as a 
plasticizer while Isopropyl alcohol and water was incorporated as a solvent. The effects of 
polymers and Isopropyl alcohol as a binder on drug release profile, gastro-resistant properties 
and matrix integrity of tablet were investigated. Developed formulations were also evaluated 
for their physical characteristics, drug content, disintegration time, friability, hardness, 
thickness, swelling index, weight variation, in vitro drug release profile etc. On the basis of 
various physical characteristic parameters, it was found that all the formulations showed good 
result. On comparative kinetic modeling study such as (Zero order, First order, Higuchi 
model and Korsmeyer-Peppas) it was found that all the formulations followed Higuchi model 
and correlation coefficient (R2) values were nearer to unity. Among those formulations, F4 
showed R2 value of Higuchi model more near as compared to the other formulations. 
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Y. Naveen Kumar et al., (2017)
57
 formulated Esmaprazole controlled release tablets by direct 
compression method using altered concentrations of Eudragit-S 100, Eudragit-L 100 and 
Eudragit-RSPO. Esomeprazole dose was fixed as 20 mg. Total weight of the tablet was 
considered as 100 mg. Polymers were used in the concentration of 20 and 40 mg. The pre 
compression blend of all formulations were subjected to various flow property tests and all 
the formulations were passed the tests. Prepared compositions were evaluated for various 
physicochemical parameters such as weight variation, hardness, friability, thickness and drug 
content. All the compositions showed results within the Pharmacopoeial limits. Dissolution 
studies showed that the formulation (F-6) showed better desired drug release pattern (i.e.) 
97.47% in 24 hours and it followed Zero order release kinetics mechanism. The optimised 
formula shall be utilized for the formulation development and other studies like 
bioequivalence study, for triumphant initiation of the product.   Hence it can be concluded 
that the prepared Esmaprazole controlled release tablets may improve the bioavailability, 
reduce the number of doses and increase patient compliance. 
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CHAPTER - 3 
 AIM AND PLAN OF WORK 
3.1 AIM OF WORK 
Duloxetine hydrochloride is one of the most commonly used antidepressant drug which is a 
selective serotonin and norepinephrine reuptake inhibitor (SSNRI) used to balance the 
Hormones such as dopamine, serotonin and norepinephrine. 
Duloxetine hydrochloride is an acid labile drug which degrades in acidic environment of the 
stomach thus leading to therapeutic inefficiency. 
The study was aimed to formulate enteric coated tablets of Duloxetine hydrochloride using 
methacrylic acid copolymer (Protectab enteric M1) to avoid degradation and to bypass the 
acidic pH of the stomach to improve the therapeutic efficacy and to increase the Duloxetine 
release in the intestine compared to the marketed Duloxetine hydrochloride enteric coated 
tablets. 
Enteric coating was done by using following polymers such as INSTA COAT MOIST 
SHIELD WHITE (ICMS), Enteric polymer protectab enteric M1. 
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3.2. PLAN OF THE WORK 
 The present work was carried out to formulate enteric coated tablets of Duloxetine 
hydrochloride and to evaluate the tablets for various parameters. It was planned to carry out 
this work as outlined below. 
1. To carry out the preformulation studies such as 
 Evaluation of API 
 Description  
 Solubility 
 Drug – excipient compatibility study 
2. To carry out the pre-compression parameters of the powder blend such as 
 Angle of repose 
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausner’ratio 
3. To carry out the drug and excipient interaction study by FT-IR.s 
4.  To formulate Duloxetine hydrochloride tablets by direct compression method. 
5.  To carry out the evaluation of uncoated tablets such as 
 Hardness 
 Thickness 
 Weight variation 
 Estimation of drug content 
 Disintegration time  
 In- vitro release studies 
6. To carry out the enteric coating of best formulation using methacrylic acid copolymer 
(Protectab enteric M1). 
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7.  To carry out the evaluation of enteric coated tablets such as 
 Thickness  
 Weight variation  
 Hardness  
 Disintegration time 
 Assay  
 In vitro dissolution studies 
8. To carry out the stability study for the best formulation at 25±2°C/60%±5%RH and 
40±2°C/75% ±5% RH for 3 months. 
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CHAPTER - 4 
MATERIALS AND METHODS 
 4.1 LIST OF MATERIALS USED AND MANUFACTURERS 
Table: 2. List of Materials Used and Manufacturers 
  
  
S. No. Materials Manufacturers 
1. Duloxetine hydrochloride MetroChem API Pvt. Ltd, Hyderabad, India. 
2. Mannitol anhydrous 
Shandong Tianli Pharmaceutical Co. Ltd, 
China. 
3. 
Microcrystalline cellulose-PH 
112 
Accent Microcell Pvt. Ltd, Gujarat, India. 
4. Calcium carbonate 
Par Drugs and Chemicals Pvt. Ltd, Vadodara, 
India. 
5. Povidone-K30 Boai NKY Pharmaceuticals Ltd, China. 
6. Croscarmelose sodium Prachin Chemicals Pvt. Ltd, Ahmedabad, India. 
7. Colloidal silicon dioxide 
Rasula Pharmaceuticals and Fine Chemicals, 
Hyderabad, India. 
8. Magnesium stearate 
Par Drugs and Chemicals Pvt. Ltd, Vadodara, 
India. 
9. Instacoat moist shield Ideal Cures Pvt. Ltd, Mumbai, India. 
10. Isopropyl alcohol 
Deepak Fertilizers and Petrochemicals 
Corporation Limited, Pune, India. 
11. Methylene dichloride 
Chemplast Sanmer Plant Ltd, Salem, 
Tamilnadu. 
12. Protectab Enteric MI Bharat Coats, Chennai, India. 
13. Iron oxide red Koel Colours Pvt. Ltd, Mumbai, India. 
14. Insta coat glow Ideal Cures Pvt. Ltd, Mumbai, India. 
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4.2 DRUG PROFILE
58 
DRUG                                   : DULOXETINE HYDROCHLORIDE 
STRUCTURAL FORMULA   
 
: 
 
MOLECULAR FORMULA      :  C18H20ClNOS. 
MOLECULAR WEIGHT         : 333.88g/mol. 
CHEMICAL  NAME 
                
: (S)-N-Methyl-3(naphthalen-1yloxy)-3-                                                 
(thiophen-2yl)propan-1-amine                        
hydrochloride(s)- Duloxetine HCl. 
CATEGORY                            : Selective serotonin and norepinephrine 
reuptake inhibitor (SSNRI). 
DOSE                                       : 60-120mg/day. 
DESCRIPTION                        
: White to slightly brownish white solid, 
crystalline powder. 
SOLUBILITY                             
:  Slightly soluble in water but soluble in 
ethanol, methanol. 
MELTING POINT                   : 169ºC - 171ºC. 
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MECHANISM OF ACTION
59
  
Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less 
potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for 
dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate and GABA receptors. 
The antidepressant and pain inhibitory actions of Duloxetine are believed to be related to its 
potentiation of serotonergic and nor adrenergic activity in the CNS. The mechanism of action 
of Duloxetine in stress urinary incontinence (SUI) has not been determined, but is thought to 
be associated with the potentiation of serotonin and nor epinephrine activity in the spinal 
cord, which increases urethral closure forces and thereby reduces involuntary urine loss.  
 
Fig: 1 Mechanism of Action of Duloxetine Hydrochloride 
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PHARMACOKINETICS
60 
Absorption  : Duloxetine is well absorbed by oral rote. The time to 
reach Cmax was typically in the range of 4 to 6 hours in 
healthy adult volunteers. 
Distribution  : Volume of distribution is 10-14L/kg. Duloxetine was 
highly bound to plasma proteins (≥95%). 
Metabolism  : In vitro studies suggest that Duloxetine may inhibit 
CYPZD6 and can be metabolized by both CYP1A2 and 
CYPZD6 into multiple inactive metabolites.  
Elimination  : The elimination halif-life of Duloxetine is about 12 hrs. 
Trace amount of (≤1%) unchanged Duloxetine was found 
in urine and about 20% excreted in faeces. 
. 
DRUG INTERACTIONS
61 
 Duloxetine is a moderate inhibitor of CYP2D6 and therefore, caution is advisable if 
administering Duloxetine together with other CYP2D6 inhibitors. Concomitant use of 
Duloxetine with drugs undergoing CYP2D6 metabolism may result in higher concentrations 
of the latter. Duloxetine with potent inhibitors of CYP1A2, like Fluvoxamine, Ciprofloxacin 
or Enoxacin, will result in higher concentrations of Duloxetine and therefore                             
co-administrations is contraindicated. 
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ADVERSE EFFECTS 
Central Nervous System           :  Dizziness, headache, tiredness, weakness, drowsiness. 
Gastro Intestinal Tract             :  Constipation, nausea, vomiting, dry mouth, stomach pain. 
Musculo Skeletal System          :   Muscle pain or cramps, fibromyalgia. 
Skin                                             :   Rashes, blisters or peeling skin. 
 
INDICATIONS
62 
Duloxetine is indicated for the treatment of : 
 Major depressive disorder 
 Generalized anxiety disorder 
 Diabetic peripheral neuropathy  
 Fibromyalgia  
 Chronic musculoskeletal pain  
 
DOSAGE AND ADMINISTRATION
63 
Treatment of major depressive disorder: 
Adult: 20-30 mg bid or 60 mg once daily. 
Maximum dose: 60 mg daily. 
Treatment of moderate to severe stress urinary incontinence in women: 
Adult: 40 mg bid. 
Diabetic neuropathy: 
Adult: 60 mg once daily. 
Maximum dose: 120 mg daily.  
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CONTRAINDICATIONS 
Duloxetine is contraindicated in patients with a known hypersensitivity to the drug. 
Concomitant use in patients taking monoamine oxidase inhibitors (MAOI) is contraindicated. 
 
MARKETED PRODUCTS 
Combac(tab), Delok(cap), Dulane(cap), Dulife(tab), Duluta-30(tab), Duvanta-30(tab), 
Dutin(cap), Sympta(tab), Nudep(cap).   
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4.3 EXCIPIENTS PROFILE 
4.3.1 MICROCRYSTALLINE CELLULOSE
64 
  
NON PROPRIETARY NAMES : BP : Microcrystalline cellulose 
JP : Microcrystalline cellulose 
PhEur : Cellulose microcrystallinum 
USP : Microcrystalline cellulose 
SYNONYMS                                      : Avicel, cellulose gel, crystalline cellulose,      
emcocel, fibrocel, tabulose, vivacel. 
  
CHEMICAL NAME                             : Microcrystalline cellulose. 
MOLECULAR STRUCTURE            :  
 
 
MOLECULAR WEIGHT                    : 404.481g/mol. 
MELTING POINT                                    : 260 to 270ºC. 
DENSITY                                                      : 1.512 to 1.668 g/cm
3
. 
DESCRIPTION                                : Microcrystalline cellulose is a purified white, 
odorless, tasteless crystalline powder. 
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SOLUBILITY                                  : Insoluble in water and organic solvent. Slightly 
soluble in 5% w/v NaoH solution. 
 
 FUNCTIONAL CATEGORY         : Absorbent, suspending agent, diluent and tablet 
disintegrant. 
 
APPLICATIONS                           : Microcrystalline cellulose is used in 
pharmaceutical industries primarily as         
binder/ diluent for tablets and capsules in both 
wet granulation and direct compression process 
and also possess lubricant and disintegrant 
properties. It is also used in cosmetics and food 
products. 
 
STORAGE                                        : It should be stored in a well closed container in    
a cool, dry place. 
 
STABILITY      : Microcrystalline cellulose is stable, though 
hygroscopic material. 
 
INCOMPATIBILITIES                    : Microcrystalline cellulose is incompatible with 
strong oxidizing agents. 
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4.3.2 MANNITOL ANHYDROUS 
 
 NON PROPRIETARY NAMES
64
 : BP: Mannitol. 
JP: D-Mannitol. 
PhEur: Mannitol. 
USP: Mannitol. 
 
SYNONYMS                                            : Cordycepic acid, emprove, manna sugar,      D-
mannite, mannite, mannitolum, mannogem, 
pearlitol. 
 
CHEMICAL  NAME                                     : D-Mannitol. 
 
 
EMPIRICAL  FORMULA                             : C6H14O6. 
 
MOLECULAR  STRUCTURE :  
 
MOLECULAR WEIGHT
65
                             : 182.17g/mol. 
 
MELTING POINT    : 166-168°C. 
 
DESCRIPTION                                               : Mannitol occurs as a white, odorless, crystalline 
powder or free-flowing granules. 
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SOLUBILITY : Soluble in alkalis and practically insoluble in ether. 
 
 FUNCTIONAL CATEGORY                       : Diluent, plasticizer, sweetening agent, tablet and 
capsule diluent and tonicity agent. 
 
APPLICATIONS                                            : Mannitol is widely used in pharmaceutical 
formulations and food products. In pharmaceutical 
preparations it is primarily used as a diluent             
(10-90% w/w) in tablet formulations, where it is of 
particular value since it is not hygroscopic and may 
thus be used with moisture-sensitive active 
ingredients. Mannitol may be used in direct-
compression tablet applications, for which the 
granular and spray-dried forms are available or in 
wet granulations. 
 
 STORAGE                                                  : The bulk material should be stored in a well-closed 
container in a cool, dry place.  
 
STABILITY  : Mannitol is stable in the dry state and in aqueous 
solutions. 
 
INCOMPATIBILITIES                                           : Mannitol solution, 20% w/v or stronger, may be 
salted out by potassium chloride or sodium 
chloride. Precipitation has been reported when a                     
25% w/v mannitol solution was allowed to contact 
plastic. Mannitol was found to reduce the oral 
bioavailability of Cimetidine.   
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4.3.3 CROSCARMELLOSE SODIUM
66 
 
NON PROPRIETARY NAMES                : BP: Croscarmellose sodium 
JP: Croscarmellose sodium 
PhEur: Croscarmellose sodium 
USP-NF: Croscarmellose sodium. 
 
 SYNONYMS                                          : Ac-Di-Sol, carmellosum natricum conexum, 
crosslinked carboxymethylcellulose sodium, 
Pharmacel XL, primellose, solutab, vivasol. 
 
CHEMICAL NAME                                     : Cellulose, carboxymethyl ether, sodium salt, 
crosslinked. 
 
EMPIRICAL  FORMULA                             : C12H30NA8O27. 
 
MOLECULAR STRUCTURE : 
 
MOLECULAR WEIGHT                             : 90,000 – 700,000. 
 
MELTING POINT
64
     : More than 205°C. 
 
DESCRIPTION                                                : Croscarmellose sodium occurs as an odorless, white 
or greyish white powder. 
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SOLUBILITY                               : Insoluble in water, although croscarmellose sodium 
rapidly swells to 4–8 times its original volume on 
contact with water. Practically insoluble in acetone, 
ethanol and toluene. 
 
FUNCTIONAL CATEGORY                      : Tablet and capsule disintegrant. 
 
APPLICATIONS : Croscarmellose sodium is used in oral 
pharmaceutical formulations as a disintegrant for 
capsules, tablets and granules. 
 
STORAGE                                                    : Croscarmellose sodium should be stored in a well-
closed container in a cool, dry place. 
 
STABILITY : Croscarmellose sodium is a stable though 
hygroscopic material. A model tablet formulation 
prepared by direct compression, with croscarmellose 
sodium as a disintegrant, showed no significant 
difference in drug dissolution after storage at 30ºC 
for 14 months. 
INCOMPATIBILITIES                                           
 
: The efficacy of disintegrants, such as croscarmellose 
sodium, may be slightly reduced in tablet 
formulations prepared by either wet-granulation or 
direct-compression process that contain hygroscopic 
excipients such as sorbitol. Croscarmellose sodium 
is not compatible with strong acids or with soluble 
salts of iron and some other metals such as 
aluminum,        mercury and zinc. 
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4.3.4 COLLOIDAL SILICON DIOXIDE
67 
 
  
NON PROPRIETARY NAMES                : BP: Colloidal anhydrous silica. 
JP: Light anhydrous silicic acid 
PhEur: Silica, colloidal anhydrous 
USP-NF: Colloidal silicon dioxide 
 
 SYNONYMS                                          : Aerosil, Cab-O-Sil, Cab-O-Sil M-5P,   colloidal 
silica, fumed silica, light   anhydrous silicic acid, 
silicic anhydride and silicon dioxide fumed. 
CHEMICAL NAME                                     : Silica. 
 
MOLECULAR STRUCTURE                    
  
: SiO2. 
 
MOLECULAR WEIGHT                             : 60.08g/mol. 
 
DESCRIPTION                                                : Colloidal silicon dioxide is a light, loose, white 
colored, odorless, tasteless, non-gritty amorphous 
powder.  
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SOLUBILITY
64
     : Practically insoluble in organic solvents, water 
and acids except hydrofluoric acid. Soluble in 
hot solutions of alkali hydroxide, forms a 
colloidal dispersion with water. 
FUNCTIONAL CATEGORY         : Absorbent, anticaking agent, glidant,  
suspending agent, tablet disintegrant. 
 
APPLICATIONS    : Colloidal silicon dioxide is widely used in 
pharmaceuticals, cosmetics and food products. 
Colloidal silicon dioxide is also used to stabilize 
emulsions and as a thickening and suspending 
agent in gels and semisolid preparations. 
STORAGE              : It should be stored in a well-closed container in 
a cool, dry place. 
STABILITY : Colloidal silicon dioxide is hygroscopic but 
adsorbs large quantities of water without 
liquefying. When used in aqueous systems        
at pH range from 0–7.5, colloidal silicon dioxide 
is effective in increasing the viscosity of a 
system. However, at a pH greater than             
7.5 the viscosity increasing properties of 
colloidal silicon dioxide are reduced; and at a 
pH greater than 10.7 this ability is lost entirely 
since the silicon dioxide dissolves to form 
silicates. 
INCOMPATIBILITIES                               : Incompatible with diethylstilbestrol preparation. 
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  4.3.5 POVIDONE68 
NON PROPRIETARY NAMES                : BP: Povidone. 
JP: Povidone. 
PhEur: Povidone. 
USP: Povidone. 
SYNONYMS                                          : Kollidon, Polyvidone, Polyvinyl Pyrrolidone,  
povidonum,  Povipharm,  PVP. 
 
CHEMICALNAME                                     : 1-Ethenyl-2-pyrrolidione homo polymers. 
 
MOLECULAR STRUCTURE                    
  
:
 
MOLECULAR WEIGHT  : 40,000g/mol. 
 
MELTING POINT
64
  
  
: 150°C. 
 
DENSITY                                                               
 
: 1.2 g/cm
3
. 
DESCRIPTION                                            
 
: Povidone occurs as a fine, white to creamy white 
colored or colorless, almost odourless, 
hygroscopic powder 
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SOLUBILITY                                                 : Freely soluble in acids, chloroform, menthol 
ethanol (95%), ketones and water. Practically 
insoluble in ether, hydrocarbon and mineral oil. 
 
FUNCTIONAL CATEGORY                      
 
: Disintegrant, dissolution enhancer, suspending 
agent and tablet binder. 
 
APPLICATIONS                                           : In tableting, povidone solutions are used as    
binders in wet-granulation process. 
 
STORAGE                                                              : The powder is hygroscopic; it should be stored in 
an airtight container in a cool place, dry place. 
 
STABILITY                                                                : Povidone darkens to some extent on heating at 
1800C, with a reduction in aqueous solubility. It is 
stable to a short cycle of heat exposure around       
110ºC-130°C.  Aqueous solutions are susceptible 
to mold growth and consequently require addition 
of suitable preservatives. 
 
INCOMPATIBILITIES                               : It forms molecular adducts in solution with 
sulfathiazole, sodium salicylate, salicylic acid, 
phenobarbital, tannin and other compounds. 
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4.3.6 CALCIUM CARBONATE
69 
 
  
NON PROPRIETARY NAMES                : BP: Calcium carbonate 
JP: Precipitated calcium carbonate 
PhEur: Calcium carbonate 
USP: Calcium carbonate 
 
 SYNONYMS                                          : 
 
Calcii carbonas, calcium carbonate carbonic acid 
calcium salt, precipitated carbonate of lime, 
precipitated chalk 
 
CHEMICAL NAME                                     : Carbonic acid, calcium salt  
 
EMPIRICAL FORMULA                            : CaCO3. 
 
MOLECULAR STRUCTURE : 
  
MOLECULAR WEIGHT : 100.09g/mol. 
 
MELTING POINT    : Melting point Decomposes at 825°C. 
 
DESCRIPTION : Calcium carbonate occurs as an odorless and 
tasteless white powder or crystals. 
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SOLUBILITY
64
                                                : Practically insoluble in ethanol (95%) and 
water. Solubility in water is increased by 
the presence of ammonia. 
 
APPLICATIONS 
: Calcium carbonate is employed as a 
pharmaceutical excipient, mainly in           
solid-dosage forms as a diluent. It is also 
used as a base for medicated dental 
preparations, as a buffering agent and as a 
dissolution aid in dispersible tablets. 
Calcium carbonate is used as a bulking 
agent in tablet sugar-coating process and as 
an opacifier in tablet film-coating. Calcium 
carbonate is also used as a food additive 
and therapeutically as an antacid and 
calcium supplement. 
 
FUNCTIONAL CATEGORY                      : Buffering agent, coating agent, colorant, 
opacifier, tablet binder, tablet and capsule 
diluent, therapeutic agent. 
 
STORAGE                                                    : Calcium carbonate should be stored in a      
well-closed container in a cool, dry place. 
 
STABILITY : Calcium carbonate is stable in room 
temperature. 
 
INCOMPATIBILITIES                                          : Incompatible with acids and ammonium 
salts. 
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4.3.7 MAGNESIUM STEARATE70 
NON PROPRIETARY NAMES                : BP: Magnesium stearate 
JP: Magnesium stearate 
PhEur: Magnesium stearate 
USP-NF: Magnesium stearate. 
 
 SYNONYMS                                          : Dibasic magnesium stearate, Magnesium 
distearate, Magnesia stearas, Magnesium 
octadecanoate, Octadecanoic acid, Magnesium 
salt, Stearic acid, Magnesium salt. 
 
CHEMICAL NAME                                     : Octadecanoic acid magnesium salt. 
 
MOLECULAR STRUCTURE                    : [CH3 (CH2)16COO]2 Mg. 
 
MOLECULAR WEIGHT                                    : 591.24g/mol. 
 
MELTING POINT
64
 
  
: 117–150ºC. 
 
DENSITY                                                                   : 1.092 g/cm3. 
 
DESCRIPTION                   : It occurs as a fine, white precipitated or milled 
impalpable powder with a faint odor and a 
characteristic taste.  
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SOLUBILITY     : Practically insoluble in ethanol, ethanol ether 
and water, slightly soluble in warm benzene 
and warm ethanol (95%). 
 
FUNCTIONAL CATEGORY                      : Lubricant. 
 
APPLICATIONS                                           : It is widely used in cosmetics, foods, and                        
pharmaceutical formulations. It is primarily 
used as a lubricant in capsule and tablet 
formulations at concentrations between         
0.2- 5.0 percent. 
 
STORAGE                                                              : It should be stored in a well-closed container in 
a cool, dry place. 
 
STABILITY                                                                 : Magnesium stearate is stable at room 
temperature. 
 
INCOMPATIBILITIES                                 : Incompatible with strong acids, alkalis and 
iron. 
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4.3.8 METHACRYLIC ACID COPOLYMER
71 
NON PROPRIETARY NAMES                : BP: Methacrylic acid–ethyl acrylate copolymer  
PhEur: Ammonio methacrylate copolymer, 
USP-NF: Ammonio methacrylate copolymer, 
Ethyl acrylate and methyl methacrylate 
copolymer, Methacrylic acid copolymer 
dispersion. 
 
SYNONYMS                                          : Acryl-EZE, Acryl-EZE MP, Eastacryl 30D, 
Protectab Enteric M1; Bharath Coat, Polymeric 
Methacrylic Acid. 
 
CHEMICAL NAME                                    : Poly (methacrylic acid, ethyl acrylate) 1:1. 
 
MOLECULAR STRUCTURE                   : 
 
MOLECULAR WEIGHT
64
                                   : About 2,50,000. 
 
DESCRIPTION                                              
 
: Synthetic cationic and anionic polymers of 
dimethyl amino ethyl methacrylates, methacrylic 
acid, and methacrylic acid esters in varying 
ratios. 
 
DENSITY    :  0.390 g/cm
3
. 
 
ACID VALUE                                                 : 300-330. 
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SOLUBILITY : Miscible in acetone and alcohols, 0.1N HCl,   
Petrolium ether. 
 
FUNCTIONAL CATEGORY                      : Film-forming agent, tablet binder, tablet diluent. 
 
APPLICATIONS                                           : Polymethacrylates are primarily used in oral 
capsule and tablet formulations as film-coating 
agents. 
 
STORAGE                                                             : Stored at temperatures between 5 and 25ºC. 
 
STABILITY                                                                  : Stable at temperatures less than 30°C. 
 
INCOMPATIBILITIES                                : Incompatibilities occur with certain 
polymethacrylate dispersions depending upon the 
ionic and physical properties of the polymer and 
solvent. 
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4.3.9 ISOPROPYL ALCOHOL
72 
 
NON PROPRIETARY NAMES : BP: Isopropyl alcohol 
JP: Isopropanol 
PhEur: Isopropyl alcohol 
USP: Isopropyl alcohol 
SYNONYMS : Alcohol isopropylico, dimethyl carbinol, isopropanol, 
petrohol, 2-propanol, rubbing alcohol. 
CHEMICAL NAME : Propan-2-ol. 
EMPIRICAL FORMULA     : C3H80. 
MOLECULAR STRUCTURE : 
 
MOLECULAR WEIGHT : 60.1g/mol. 
MELTING POINT
64 
: - 88.5
0
C. 
DESCRIPTION : Isopropyl alcohol is a clear, colorless, volatile, 
flammable liquid with a characteristic, spirituous 
odor resembling that of a mixture of ethanol and 
acetone. It has a slightly bitter taste. 
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SOLUBILITY : Miscible with benzene, chloroform,             
ethanol (95%), ether, glycerin and water. 
Soluble in acetone, insoluble in salt. 
FUNCTIONAL CATEGORY : Disinfectant, solvent. 
APPLICATIONS : Isopropyl alcohol is used in cosmetics and 
pharmaceutical formulations, primarily as a 
solvent in topical formulations. Isopropyl 
alcohol is also used as a solvent both for tablet 
film-coating and for tablet granulation. 
STORAGE :  It should be stored in an air tight container in       
a cool, dry place. 
STABILITY : Isopropyl alcohol is stable at room temperature.  
INCOMPATIBILITIES : Incompatible with oxidizing agents such as 
hydrogen peroxide and nitric acid, which cause 
decomposition. Isopropyl alcohol may be salted 
out from aqueous mixtures by the addition of 
sodium chloride, sodium sulfate and other salts    
or by the addition of sodium hydroxide. 
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4.3.10 METHYLENE DI CHLORIDE73 
 
  
NON PROPRIETARY NAMES : Methylene di chloride 
 
SYNONYMS    : Solmethine, narkotil, solaesthin. 
 
CHEMICAL NAME : Dichloromethane. 
 
EMPIRICAL FORMULA    : CH2Cl2. 
 
MOLECULAR STRUCTURE : 
 
MOLECULAR WEIGHT :  84.93g/mol. 
 
MELTING POINT : -97
0
C. 
 
DESCRIPTION
 
 
 
 
 
 
 
 
 
 
 
 
 
: Colorless, transparent, volatile liquid with 
pungent smell, soluble in water of about 50 
times the volume, soluble in phenol, 
aldehyde, ketone, acetic acid, tri ethyl 
phosphate, ethyl acetoacetate, 
cyclohexylamine. Miscible with other 
chlorinated hydrocarbons and ethanol. 
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SOLUBILITY
64 
: Miscible in ethyl acetate, alcohol, hexanes, 
methanol, diethyl ether, n-octanol, acetone. 
 
APPLICATIONS : Dichloromethane is largely used in the 
manufacture of safe film, polycarbonate, the 
rest used as paints, solvents, metal 
degreasing agent, gas aerosol spray, 
polyurethane foam, mold release agent and 
paint remover. It is also used as the reaction 
medium in the pharmaceutical industry for 
the preparation of Ampicillin, Ampicillin 
and Cephalosporin. 
 
STORAGE : Methylene dichloride should be stored at 
room temperature in air tight container in a 
cool, dry place. 
 
STABILITY : In the absence of moisture at ordinary 
temperature dichloromethane is relatively 
stable. 
INCOMPATIBILITIES : Methylene di chloride is incompatible with 
alkali metals, strong oxidizing agents, 
strong bases and oxides of nitrogen, zinc, 
aluminum, water, magnesium and amines. 
Liquid methylene chloride will attack some 
forms of plastics, rubber and coatings.  
 CHAPTER 4                                                                         MATERIALS AND METHODS 
S.B.C.P                                   DEPARTMENT OF PHARMACEUTICS Page 63 
 
4.3.11 LAKE IRON OXIDE RED74 
 
  
NON PROPRIETARY NAMES                : Iron oxide. 
SYNONYMS                                               : Anhydrous ferric oxide, anhydrous iron oxide, 
ferroxide, hematite, pigment red, red ferric 
oxide, sicovit.   
   
CHEMICAL NAME                                             : Iron oxide red. 
 
EMPIRICAL FORMULA                                    : Fe203. 
 
MOLECULAR WEIGHT                                   : 159.70g/mol. 
 
MOLECULAR STRUCTURE                           :
 
  DESCRIPTION                                                   
 
: Iron oxides occur as yellow, red, black or brown 
powder. The color depends on the                  
particle size, shape and crystal structure. 
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SOLUBILITY
64 
: Soluble in mineral acids, insoluble in water. 
 
FUNCTIONAL CATEGORY   : Colorant. 
 
APPLICATIONS                                                   : Iron oxides are widely used in cosmetics, foods 
and pharmaceutical applications as colorants and 
UV absorbers. As inorganic colorants they are 
becoming of increasing importance as a result of 
the limitations affecting some synthetic organic 
dyestuffs.  
 
STORAGE    : Iron oxides should be stored in well-closed 
containers in a cool, dry place. 
 
STABILITY : Iron oxide red is stable at room temperature. 
 
INCOMPATIBILITIES                                          : Iron oxide is incompatible with common organic 
acids, mineral acids and oxidizing agents. 
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4.4 INSTRUMENTS USED AND MANUFACTURERS 
Table: 3. List of Instruments Used and Manufacturers 
S. No INSTRUMENTS MANUFACTURERS 
1.  Single pan electronic balance Sartorious, Germany. 
2.  12 Station D/B Tooling compression machine Fluid pack, Ahmedabad, india. 
3.  R&D Mini coater Ideal Cure Pvt Ltd, Mumbai, India. 
4.  Vernier calipers Mitutoyo, Japan. 
5.  Dissolution Test Apparatus Electro lab, Mumbai, India. 
6.  Hardness Tester Campbell electronics, Mumbai. 
7.  Friability Test Apparatus Electro lab, ED-2L, India. 
8.  Sieves 
Jayant Scientific Ind, Mumbai, 
India. 
9.  Disintegration Test Apparatus Electro lab, ED-2L, India. 
10.  FT-IR spectrophotometer IR Affinity-1S Shimadzu, Japan. 
11.  HPLC LC-10, Shimadzu, Japan. 
12.  UV- spectrophotometer UV-1800, Shimadzu, Japan. 
13.  Stability chamber Thermo lab, Mumbai 
14.  Blister packing machine 
Elmach Packages Pvt Ltd, 
Mumbai, India. 
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4.5 METHODOLOGY 
4.5.1 PREFORMULATION STUDIES
72 
Preformulation is defined as a stage of development during which the physico-chemical 
properties of the drug substance is characterized and established. A complete knowledge of 
the relevant therapeutic and physico-chemical properties of the drug enables determination of 
its proper formulation and delivery method. The overall objective of preformulation testing is 
to generate information useful in developing the formulation which is stable and bio-
available. Further the use of preformulation parameter maximize the chances in formulating 
an acceptable, safe, efficacious and stable product. The goals of preformulation studies are to 
choose the correct form of the drug substance, evaluate its physical properties and generate a 
thorough understanding of the material’s stability under the conditions that will lead to 
development of an optimal drug delivery system. 
Objectives of preformulation studies 
 To develop the elegant dosage forms (stable, effective & safe). 
 To understand the physical description of a drug substance before dosage form 
development. 
  Rational development of a dosage form of a drug substance before dosage form 
development.  
 It provides information to the formulator to design an optimum drug delivery system. 
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4.5.1.1 ORGANOLEPTIC PROPERTIES 
The organoleptic properties like color, odor and taste of the API was evaluated. 
a) Color: A small quantity of Duloxetine HCl was taken in a butter paper and viewed in 
a well-illuminated place. 
b) Taste and odor: Very less quantity of Duloxetine HCl was used to assess the taste 
with the help of tongue as well as smelled to get odor. 
4.5.1.2 SOLUBILITY TEST
 73 
Solubility of Duloxetine HCl in water, methanol and ethanol was determined by 
using sonicator at room temperature.  The solubility specifications as per I.P was mentioned 
in table: 4. 
Table: 4. Solubility Specifications  
Solubility Approximate Volume of Solvent in ml per gm of Solute 
Very soluble Less than 1 
Freely soluble 1 to 10 
Soluble 10 to 30 
Sparingly soluble 30 to 100 
Slightly soluble 100 to 1000 
Very slightly soluble 1000 to 10000 
Practically insoluble More than 10000 
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4.5.1.3 DRUG - EXCIPIENT COMPATIBILITY STUDIES 
In the tablet dosage forms the drug is in intimate contact with one or more excipients, 
the latter could affect the stability of the drug. Knowledge of drug-excipient interactions is 
very useful to the formulators in selecting appropriate excipients.  
Method  
Compatibility study was performed by preparing blends of different excipients with 
API. The blends were stored at room temperature for 30 days. Physical observation has been 
carried out at the initial stage, after 15 days and after 30 days. The drug excipients 
compatibility profiles were shown in table: 5. 
Table: 5. Drug- Excipient Compatibility Study 
S.No. Composition 
Ratio  
(Drug : Excipient) 
1.  Duloxetine hydrochloride 
1 
2.  Duloxetine hydrochloride + Mannitol anhydrous 1:1 
3.  Duloxetine hydrochloride + Calcium carbonate 1:1 
4.  Duloxetine hydrochloride + Microcrystalline cellulose 1:1 
5.  Duloxetine hydrochloride + Povidone-K30 1:1 
6.  Duloxetine hydrochloride + Colloidal silicon dioxide 1:1 
7.  Duloxetine hydrochloride + Croscarmellose sodium 1:1 
8.  Duloxetine hydrochloride + Magnesium stearate 1:1 
9.  Duloxetine hydrochloride + Instacoat moist shield white 1:1 
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4.5.2 FT- IR SPECTRAL ANALYSIS
74  
Infrared spectra matching approach was used for the detection of any possible 
chemical reaction between the drug and the excipients. A physical mixture (1:1) of drug and 
excipients was prepared and mixed with suitable quantity of potassium bromide. About 
100mg of this mixture was compressed to form a transparent pellet using hydraulic press at 
10 tons pressure and scanned between 4000 - 400 cm
-1
 in a shimadzu FT-IR 
spectrophotometer. The IR spectrum of the physical mixture was compared with those of 
pure drug and excipients and matching was done to detect any appearance or disappearance 
of peaks. 
4.5.3 EVALUATION OF PRECOMPRESSION PARAMETERS 
4.5.3.1 MICROMERITIC PROPERTIES 
4.5.3.1.1 ANGLE OF REPOSE
75, 76 
Angle of repose is defined as the maximum angle possible between the surface of the 
pile of powder and the horizontal plane. The angle of repose is designated by θ. It can be 
determined by funnel method. The powder blend was passed through funnel so that they form 
a pile. The height (h) of the pile and the radius of the pile (r) were measured and angle of 
repose was calculated using following formula. 
   
 
 
Where, 
θ = Angle of repose. 
h = Height of the pile. 
r = Radius of the pile. 
The flow properties and corresponding angle of repose as per USP was listed in table: 6. 
  
Tan θ = h/r  
  θ = Tan-1 (h/r) 
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Table: 6. Flow Properties and Corresponding Angle of Repose as per USP 
Flow Property Angle of Repose (θ) 
Excellent 25 – 30 
Good 31 – 35 
Fair 36 – 40 
Passable 41 – 45 
Poor 46 – 55 
Very Poor 56 – 65 
Very Very Poor ˃ 66 
 
4.5.3.1.2 BULK DENSITY AND TAPPED DENSITY
77, 78 
An accurately weighed quantity of the powder (W), was carefully poured into the 
graduated cylinder and the volume (V0) was measured. Then the graduated cylinder was 
closed with lid, set into the density determination apparatus (bulk density apparatus). The 
density apparatus was set for 100 taps and after that, the volume (Vf) was measured and the 
operation was continued till the two consecutive readings were equal. The bulk density and 
tapped density were calculated using the following formulas 
 
 
Where, 
W= Weight of powder, 
V0= Initial volume of powder, 
Vf = Final volume of powder. 
  
Bulk density = W/V0 
Tapped density = W/Vf 
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4.5.3.1.3 MEASUREMENT OF POWDER COMPRESSIBILITY 
 A) Compressibility Index
79 
The term compressibility is the ability to reduce the volume under pressure. The 
compressibility index of the powder was determined by the carr’s compressibility index. It is 
used as an indication of the flowability of a powder. A compressibility index greater than 25 
is an indication of poor flowability and below 15 indicates good flowability.  
  
                            
                                                
       
B) Determination of Hausner’s Ratio 
The hausner’s ratio is a number that is correlated to the flowability of a powder or 
granular material. The ideal range should be 1.2 - 1.5. Hausner’s ratio was determined by the 
ratio of tapped density and bulk density. The scale of flowability was shown in table: 7. 
 
 
Table: 7. Scale of Flowability 
Compressibility Index (%) Flow Character Hausner’s Ratio 
01-10 Excellent 1.00-1.11 
11- 15 Good 1.12-1.18 
16- 20 Fair 1.19-1.25 
21- 25 Passable 1.26-1.34 
26- 31 Poor 1.35-1.45 
32- 37 Very poor 1.46-1.59 
 
  
Compressibility index =   
𝐓𝐚𝐩𝐩𝐞𝐝 𝐝𝐞𝐧𝐬𝐢𝐭𝐲−𝐁𝐮𝐥𝐤 𝐝𝐞𝐧𝐬𝐢𝐭𝐲
𝐓𝐚𝐩𝐩𝐞𝐝 𝐝𝐞𝐧𝐬𝐢𝐭𝐲
  ×100 
 
Hausner’s ratio =  
𝐓𝐚𝐩𝐩𝐞𝐝 𝐝𝐞𝐧𝐬𝐢𝐭𝐲
𝐁𝐮𝐥𝐤 𝐝𝐞𝐧𝐬𝐢𝐭𝐲
 ×100 
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4.5.4 FORMULATION OF DULOXETINE HYDROCHLORIDE UNCOATED 
TABLETS   
  Duloxetine Hydrochloride tablets (20 mg) were prepared by direct compression 
method as per the composition shown in Table: 8. Five formulations (F-I to F-V) were 
prepared by direct compression method. Various steps (sieving, dry mixing, lubrication and 
compression) involved in the tablet production by direct compression method were 
mentioned below. 
 
DIRECT COMPRESSION METHOD
80 
 
Sieving 
The active ingredient was passed through the sieve # 40. The other ingredients given 
in the formulation table were passed separately through the same sieve. 
 
Dry mixing        
All the materials (including the active ingredient) were taken in a poly bag and mixed 
for 10 minutes for uniform mixing. 
 
Lubrication  
 Magnesium stearate and talc were passed through the sieve # 60 and mixed together 
with the powder mixture in a polybag for 5 minutes to get a uniform blend. 
 
Compression  
Finally, the powder mixture was compressed into tablets using rotary tablet 
compression machine of 7.14 mm round shape punches and dies.   
  
 CHAPTER 4                                                                         MATERIALS AND METHODS 
S.B.C.P                                   DEPARTMENT OF PHARMACEUTICS Page 73 
 
ENTERIC COATING OF TABLETS: 
Seal coating 
 Accurately weighed ethyl cellulose was milled using colloidal mill for 20 minutes to 
reduce particle size and dissolved in acetone to form uniform coating solution and applied 
into uncoated tablets.  
 
Moisture Prior coating 
 The solid material of insta coat moisture shield white was dissolved in isopropyl 
alcohol and then mixed with methylene dichloride and uniformly mixed by using colloidal 
mill for 30 minutes and then applied into uncoated tablets. This process of moisture prior 
coating is performed after seal coating process.  
 
Enteric coating 
 Protectab enteric M1 bharath coat (methacrylic acid co polymer) powder was mixed 
with isopropyl alcohol. Iron oxide red was added to this solution and milled using colloidal 
mill to form uniform coating solution and then applied into uncoated tablets. 
 
Polish coating 
The tablets obtained are smooth and evenly colored but have a dull surface 
appearance. Polishing is carried out in canvas lined coating pans and the process consists of 
applying thin layer of waxy materials to impart shine to the finished tablets. 
 
Packing details 
The prepared tablets were packed in Alu-Alu Blister packing. 
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FORMULATION FLOW CHART OF DIRECT COMPRESSION METHOD 
 
 
STEPS 
SIEVING 
DRY MIXING 
LUBRICATION 
COMPRESSION 
SEAL COATING 
All the ingredients were 
passed through sieve # 40. 
Mixed for 10 minutes in a 
polybag.              
Magnesium stearate and talc 
were passed through sieve # 60 
and mixed with powder blend 
for 5 minutes. 
The powder mixture was 
compressed into tablets using 
rotary tablet compression 
machine of 7.14 mm punch and 
die. 
Accurately weighed ethyl cellulose 
was dissolved in acetone and 
milled for 20 minutes. 
 
 CHAPTER 4                                                                         MATERIALS AND METHODS 
S.B.C.P                                   DEPARTMENT OF PHARMACEUTICS Page 75 
 
  
 
  
MOISTURE PRIOR COATING 
 
ENTERIC COATING 
 
PACKING DETAILS 
 
Insta coat moisture shield white 
was dissolved in isopropyl 
alcohol and then mixed with 
methylene dichloride. 
Protectab enteric M1 bharath 
coat powder was mixed with 
isopropyl alcohol. Iron oxide 
red was added to this solution. 
The tablets were packed in   
Alu – Alu Blister packing. 
POLISH COATING Polishing is carried out in canvas 
lined coating pans and the process 
consists of applying waxy 
material to impart shine to the 
finished tablets. 
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Table: 8. Composition of Duloxetine Hydrochloride Enteric Coated Tablets 
 
Ingredients 
Quantity per Tablet (mg) 
FORMULATION CODE 
F-I F-II F-III F-IV F-V 
Duloxetine hydrochloride   20.00 20.00 20.00 20.00 20.00 
Mannitol anhydrous 50.00 45.00 45.00 40.00 40.00 
Microcrystalline cellulose - 
PH 112 
45.00 45.00 35.00 30.00 30.00 
Calcium carbonate - 5.00 15.00 25.00 25.00 
Povidone-K30 10.00 10.00 10.00 10.00 10.00 
Croscarmellose sodium 16.00 16.00 16.00 16.00 16.00 
Colloidal silicon dioxide 1.00 1.00 1.00 1.00 1.00 
Magnesium stearate 3.00 3.00 3.00 3.00 3.00 
Average weight of each 
uncoated tablet 
145.00 145.00 145.00 145.00 145.00 
Seal Coating 
Insta coat moist shield 
white 
- - - 3.00 3.00 
Isopropyl alcohol - - - 20.00 20.00 
Methylene dichloride - - - 10.00 10.00 
Enteric Coating 
Protectab Enteric M1  - - - 5.80 11.80 
Isopropyl alcohol - - - 30.00 60.00 
Methylene dichloride - - - 30.00 60.00 
 Ironoxide red - - - 0.20 0.20 
Polish Coating 
Insta coat glow - - - 1.00 1.00 
Isopropyl alcohol - - - 3.50 3.50 
Methylene dichloride - - - 3.50 3.50 
Average weight of each  
enteric coated tablet 
- - - 155.00 161.00 
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4.5.5 POST COMPRESSION PARAMETERS 
The compressed tablets were evaluated for the following parameters. 
4.5.5.1 GENERAL APPEARANCE 
The tablets should be free from cracks, depressions, pinholes etc. The color and polish 
of the tablets should be uniform on whole surface. The surface of the tablets should be 
smooth. The tablets were examined externally under a biconvex lens for surface cracks, 
depressions and pinholes. 
4.5.5.2. THICKNESS TEST  
Thickness of the tablet was measured by using vernier caliper. Tablet thickness 
should be controlled within a ± 5% variation of standard value. Thickness values were 
expressed in millimeter. 
4.5.5.3. HARDNESS TEST
81 
“Hardness is defined as the resistance of the tablet against the applied force till it 
breaks”. Hardness (diametric crushing strength) is the force required to break a tablet across 
the diameter. To determine the need for pressure adjustments on the tablet compression 
machine, hardness can affect the disintegration. For each formulation, the hardness of 5 
tablets was determined using a Monsanto hardness tester. The tablet is placed across the 
diameter in between the spindle and anvil. The knob is adjusted to hold the tablet in position. 
The pressure is increased slowly to break the tablet. The value was expressed in Kg/cm
2
. 
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4.5.5.4. WEIGHT VARIATION TEST
82 
Twenty tablets were selected at random and average weight was determined. Then 
individual tablets were weighed and the individual weight was compared with the average 
weight. Not more than two of the tablets weight should deviate from the average weight by 
more than the percentage deviation listed in the accompanying table and none should deviate 
from the average weight by more than twice that percentage deviation mentioned in table: 9. 
Table: 9. Weight Variation of Tablets and Percentage Deviation 
Average Weight of Tablets in I.P (mg) Percentage Deviation (%) 
130 or less ± 10 
130 – 324 ± 7.5 
More than 324 ± 5 
 
Percentage deviation of the tablets were calculated by using the following formula  
Percentage deviation = 
                     )−                            ) 
                           )
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4.5.5.5 FRIABILITY
83 
Friability is the phenomenon where the surface of the tablet is damaged or shown a 
site of damage due to mechanical shock. It is tested by using Roche friabilator. Friabilator is 
made up of a plastic drum fixed with a machine which rotates at 25 rpm for 100 revolutions. 
Tablet falls from 6 inches height in each turn within the apparatus. The percentage friability 
of the tablets were calculated by the formula. 
  
 
 
Where, 
W1 = Weight of tablets before testing.  
W2 = Weight of tablets after testing. 
According to B.P/I.P = Percentage of friability should be not more than 0.8% - 1.0%. 
 
4.5.5.6 DISINTEGRATION TEST
84 
The disintegration test was carried out according to I.P procedure on six tablets using 
disintegration test apparatus with disks in 0.1 N HCl (pH 1.2) maintained at 37
0
C ± 2
0
C for          
2 hours. After 2 hours 0.1 N HCl was replaced with phosphate buffer 6.8 pH.  A disk was 
added to each tube and operated for further 60 minutes. The disintegration time of each tablet 
was recorded. 
  
Percentage Friability = W1 – W2/W1 × 100 
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4.5.5.7 ASSAY OF DULOXETINE HYDROCHLORIDE BY HPLC METHOD
85 
Chromatographic Conditions  
Column  : Inertsil ODS (250x 4.6 mm) C8 column. 
Mobile phase : 55:37:8 V/V (Buffer: acetonitrile (ACN):methanol. 
Buffer  : 0.3% w/v solution of potassium dihydrogen phosphate. Adjust 
to pH 5.7 with orthophosphoric acid. 
Flow rate : 2.0 ml/minute. 
Injection volume : 20 µl. 
Wavelength : 240 nm. 
Column Temperature  : 30ºC. 
 
Preparation of Mobile Phase 
Buffer pH 5.7, ACN and methanol were mixed in the ratio of 55:37:8 v/v. 
Preparation of Standard Solution 
Accurately weighed 20 mg of Duloxetine hydrochloride was transferred to a 20ml 
volumetric flask, dissolved and diluted to the mark with methanol to obtain a standard 
solution of 1000 μg/ml. This solution (1 ml) was further diluted to 10 ml with mobile phase 
to obtain a working standard stock solution of 100μg/ml for the HPLC method. 
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Preparation of Sample Solution 
Twenty tablets were weighed and finely powdered. A mass equivalent to 20 mg of 
Duloxetine hydrochloride was weighed and transferred in a 100 ml volumetric flask, mixed 
with methanol (60 ml) and sonicated for 20 min. The solution was filtered through whatman 
filter paper and the residue was washed thoroughly with methanol. The filtrate and washings 
were combined in a 100 ml volumetric flask and diluted to the mark with methanol. An 
aliquot of this solution (0.2 ml) was further diluted to 10 ml with methanol to obtain a 
solution containing 4 µg/ml of Duloxetine hydrochloride and subjected to HPLC analysis. 
Sample Injection Procedure 
20 µl of filtered sample solution and standard solution were separately injected into 
HPLC system. The chromatogram was recorded and responses were measured for major 
peaks. 
The content of Duloxetine hydrochloride in the powder mixture was calculated by 
using the following equation. 
 
 
 Where,  
P – Purity of Duloxetine hydrochloride. 
Avg. Wt – Average weight in mg. 
 
 
 
 
 
 
 Content of Duloxetine hydrochloride = 
Sample area
Standard area
 × 
Standard weight
Sample weight
 × 
𝑃
100
 × Avg. Wt 
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 4.5.5.8 IN VITRO DRUG RELEASE STUDIES
86 
Dissolution Parameters
 
Type of apparatus : U.S.P. Type II (paddle) 
Medium : 0.1N HCL for 2hr, Phosphate buffer pH 6.8 for 45 min 
RPM : 100 
Temperature  : 37°C ± 0.5ºC 
Volume of medium : 900 ml 
Sampling intervals : 5, 10, 15, 20, 30, 45 min. 
Sampling volume : 10 ml 
Method of analysis : UV Spectrophotometer 
Wavelength : 289 nm. 
 
Preparation of 0.1 N Hydrochloric Acid 
Place 8.5 ml of concentrated hydrochloric acid into the 1000 ml volumetric flask and 
the volume was made up with de-mineralized water. 
Preparation of pH 6.8 Phosphate Buffer 
Place 14.40 gm of dihydrogen phosphate and 5.72 gm of potassium hydrogen 
phosphate in a 1000 ml volumetric flask and make upto 1000 ml with de-mineralized water. 
Procedure  
Drug release studies were carried out by using USP Type II paddle dissolution test 
apparatus at 100 rpm for 2 hrs in 0.1 N HCI (900ml) maintained at 37°C ± 0.5ºC. 10 ml of 
sample was taken and analyzed by using UV spectrophotometer at 289 nm. Then the 
dissolution medium was replaced with 6.8 pH Phosphate buffer (900 ml) and tested for drug 
release for 45 minutes at 37°C ± 0.5ºC temperature and 100 rpm speed. After 5, 10, 15 and 45 
minutes, 10ml samples were taken out and 10 ml volume of fresh phosphate buffer pH 6.8 
was added to kept volume of dissolution medium constant and sample was analyzed using 
UV spectrophotometer at 289 nm. 
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4.5.5.9 STABILITY STUDIES
87 
Stability is defined as the capacity of a drug substance or drug product to remain 
within the established specifications which maintains its identity, strength, quality and purity 
throughout the retest or expiration dating period. The objective of stability study is to 
determine the shelf life, namely the time period of storage at a specified condition within 
which the drug product still meets its established specifications. Stability study is of three 
types that is physical, chemical and microbial stability. Various factors like oxygen, water, 
temperature, pH, moisture, light and concentration affect the stability.  
4.5.5.9.1 Purpose of Stability Testing
88 
The purpose of stability testing is to provide evidence of how the quality of an active 
pharmaceutical ingredient (API) or finished pharmaceutical product (FPP) varies with time 
under the influence of a variety of environment factors such as temperature, humidity and 
light. The stability programme also includes the study of product- related factors that 
influences its quality, for example, interaction of API with excipients, container closure 
systems and packaging materials.  
4.5.5.9.2 ACCELERATED STABILITY STUDIES
89 
Generally, the observation of the rate at which the product degrades under normal 
room temperature requires a long time. To avoid the undesirable delay, the principles of 
accelerated stability studies are adopted by accelerating the parameters such as temperature, 
humidity and light. 
  The International Council for Harmonization (ICH) guidelines titled stability testing 
for new drug substances and product (QIA) describes the stability test requirements for drug 
registration application in the European Union, Japan and United States of America. ICH 
guidelines specifies the length of study and storage conditions. 
 Long term testing: 25 ± 2°C/60% ± 5% RH for 12 months. 
 Accelerated testing: 40 ± 2°C/75% ± 5% RH for 6 months.     
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Procedure 
Stability studies were carried out for optimized formulation (F-V) at 
25±2°C/60%±5%RH and 40±2°C/75%±5%RH for 3 months. The selected clear ALU-ALU 
packed formulations were stored at 25±2°C/60%±5%RH and 40±2°C/75%±5%RH for 3 
months and their physical appearance, average weight, thickness, hardness, friability, 
disintegration test, assay and in vitro drug release were evaluated at specified intervals of 
time (every month). 
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CHAPTER-5 
RESULTS AND DISCUSSION 
Duloxetine hydrochloride is an acid labile drug which degrades in acidic environment 
of the stomach thus leading to therapeutic inefficiency. The present study was aimed to 
formulate enteric coated tablets of Duloxetine hydrochloride to avoid degradation and to 
bypass the acidic pH of the stomach. The work was carried out to delay the release of 
Duloxetine hydrochloride by using enteric polymer. The powder blends of different 
fomulations were evaluated for precompression parameters such as angle of repose, bulk 
density, tapped density, compressibility index and hausner’s ratio. The prepared tablets were 
evaluated for various post compression parameters such as general appearance, hardness, 
thickness, weight variation, friability, disintegration time and in vitro drug release study. The 
optimized formulation was subjected for stability study.  The results were presented in 
appropriate tables and figures. 
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5.1 PREFORMULATION STUDIES 
5.1.1 ORGANOLEPTIC PROPERTIES  
The organoleptic properties of Duloxetine hydrochloride was presented in table: 10. 
Table: 10. Organoleptic Properties of Duloxetine Hydrochloride (API) 
Tests Specifications as per I.P Observation 
Color White White 
Taste Bitter Bitter 
Odor Odorless Odorless 
Discussion:  
The organoleptic properties like color, odor and taste of the API were evaluated. The 
color of Duloxetine hydrochloride was found to be white. Duloxetine hydrochloride does not 
show any characteristic odor and the taste was found to be bitter. Duloxetine hydrochloride 
showed similar color, taste and odor as per the I.P specifications. 
5.1.2 SOLUBILITY TEST 
The solubility profile of Duloxetine hydrochloride was mentioned in table: 11. 
Table: 11. Solubility Profile of Duloxetine HCl (API) 
Raw Material (API) Solubility 
Duloxetine hydrochloride 
Very soluble in DMSO 
Soluble in methanol 
Sparingly soluble in water 
Discussion:  
 The solubility studies of drug (API) revealed that Duloxetine HCI was very much soluble in 
DMSO, soluble in methanol, ethanol and sparingly soluble in water.   
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5.1.3 DRUG – EXCIPIENTS COMPATIBILITY STUDIES 
Compatibility study was performed by preparing blends of different excipients with 
API.        The blends were stored at room temperature for 30 days. Physical observation has 
been carried out at the initial stage, after 15 days and after 30 days. The drug excipients 
compatibility profiles were shown in table: 12. 
Table: 12. Drug - Excipients Compatibility Study 
 
S. No. 
 
Composition 
Description 
INITIAL 
PERIOD 
AFTER 15 
DAYS 
AFTER 30 
DAYS 
1. Duloxetine hydrochloride 
White to off 
white powder 
NCC* NCC 
2. 
Duloxetine hydrochloride + 
Mannitol anhydrous 
White to off 
white powder 
NCC NCC 
3. 
Duloxetine hydrochloride + 
Microcrystalline cellulose 
White to off 
white powder 
NCC NCC 
4. 
Duloxetine hydrochloride + Calcium 
carbonate 
White to off 
white powder 
NCC NCC 
5. 
Duloxetine hydrochloride + 
Povidone 
White to off 
white powder 
NCC NCC 
6. 
Duloxetine hydrochloride + 
Croscarmellose sodium 
White to off 
white powder 
NCC NCC 
7. 
Duloxetine hydrochloride + 
Colloidal silicon dioxide 
White to off 
white powder 
NCC NCC 
8. 
Duloxetine hydrochloride + 
Magnesium stearate 
White to off 
white powder 
NCC NCC 
9. 
Duloxetine hydrochloride + Insta 
coat moist shield 
White to off 
white powder 
NCC NCC 
Note: *NCC – No Characteristic Change 
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Discussion: 
From the drug excipients compatibility study, it was observed that there was no 
characteristic change found between drug and excipients. Thus it was concluded that the 
excipients selected for the formulation were compatible with Duloxetine hydrochloride and 
suitable for formulation development. 
5.2 FT-IR SPECTRAL STUDIES 
FT- IR studies of the pure Duloxetine hydrochloride, excipients and combination of 
drug and excipient was carried out to found any interaction between drug and excipients used 
in the formulation. FT-IR study was performed using IR spectroscopy (SHIMADZU).  The 
I.R spectra of drug and excipients were shown in fig: 2 to 6 and in table: 13 to 17 
respectively. 
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 Fig: 2 FT- IR Spectrum of Pure Duloxetine Hydrochloride 
Table: 13. FT- IR Spectral Data of Pure Duloxetine Hydrochloride 
S. No. Wave Number (cm
-1
) Functional Group 
1 2962 Aromatic C- H stretching 
2 2769 Alkane C- H stretching 
3 1581 Aromatic N- H bending 
4 1465 Aromatic C = C stretching 
5 1396 Alkane C- H bending 
6 1234 Aromatic C - N stretching 
7 1095 Ether C - O stretching 
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Fig: 3 FT- IR Spectrum of Croscarmellose sodium 
Table: 14. FT- IR Spectral Data of Croscarmellose sodium 
S. No. Wave Number (cm
-1
) Functional Group 
1 3348 Alcoholic O - H stretching 
2 2900 Alkane C - H stretching 
3 1427 Alkane C - H bending 
4 1056 Alcoholic C - O stretching 
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Fig: 4 FT- IR Spectrum of Protectab Enteric M1 
Table: 15. FT- IR Spectral Data of Protectab Enteric M1 
S. No. Wave Number (cm
-1
) Functional Group 
1 2931  O - H stretching 
2 1728  C = O stretching 
3 1373 Alkane C - H bending 
4 1257 Acid C - O stretching 
5 1018 C -O stretching 
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Fig: 5 FT- IR Spectrum of Duloxetine Hydrochloride + Croscarmellose sodium 
Table: 16. FT- IR Spectral Data of Duloxetine Hydrochloride + Croscarmellose sodium 
S. No. Wave Number (cm
-1
) Functional Group 
1 2962 Aromatic C - H stretching 
2 2777 Alkane C - H stretching 
3 1581 Amine N - H bending 
4 1396 Alkane C - H bending 
5 3348 Alcoholic O - H stretching 
6 2422 Alkane C - H stretching 
7 1465 Aromatic C = C stretching 
8 1095 Ether C – O stretching 
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Fig: 6 FT-IR Spectrum of Duloxetine Hydrochloride + Protectab Enteric M1 
Table: 17. FT-IR Spectral Data of Duloxetine Hydrochloride + Protectab Enteric M1 
S. No. Wave Number (cm
-1
) Functional Group 
1 2962 Aromatic C- H stretching 
2 1581 Aromatic N- H bending 
3 1465 Aromatic C = C stretching 
4 1396 Alkane C- H bending 
5 1234 Aromatic C - N stretching 
6 1095 Ether C - O stretching 
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Table: 18. Comparative FT- IR Spectral Data of Drug and Excipients 
 
Discussion: 
FT-IR spectroscopic studies indicated that the drug is compatible with all the 
excipients. The FT-IR spectrum of physical mixture showed all the characteristic peaks of 
Duloxetine hydrochloride, thus conforming that no interaction of drug occurred with the 
components of the formulation.  
  
Compounds 
Functional Groups 
Aromatic 
C - H 
stretching 
Alkane 
C - H 
stretching 
N-H 
Amine 
bending 
Aromatic 
C = C 
stretching 
Alkane 
C- H 
bending 
Aromatic   
C- N 
stretching 
C- O 
Ether 
stretching 
Drug 
(Duloxetine 
hydrochloride) 
2962 2769 1581 1465 1396 1234 1095 
Drug + CCS 2962 2777 1561 1465 1396 1234 
 
1095 
 
Drug + 
Protectab 
enteric M1 
2962 2769 1581 1465 1372 1234 1095 
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5.3 MICROMERITIC PROPERTIES 
Table: 19. Precompression Parameters 
 
Formulation 
Code 
 
Angle of 
Repose 
(θ) 
Bulk 
Density 
(g/cm
3
) 
 
Tapped 
Density 
(g/cm
3
) 
Compressibility 
Index (%) 
Hausner’s 
Ratio 
F-I  28.56±0.3 0.562±0.2 0.690±0.5 18.55±0.7 1.15±0.7 
F-II 30.09±0.7 0.640±0.1 0.745±0.3 14.09±0.2 1.16±0.6 
F-III 25.46±0.2 0.305±0.3 0.351±0.5 13.11±0.1 1.15±0.2 
F-IV  24.98±0.6 0.317±0.7 0.367±0.1 13.63±0.6 1.15±0.5 
F-V 24.23±0.1 0.310±0.5 0.360±0.2 13.89±0.3 1.17±0.3 
        *All the values are expressed as mean ± SD, n=3. 
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Discussion: 
  Duloxetine hydrochloride powder blends were evaluated for different precompression 
parameters and the results are mentioned in table: 19. 
Angle of Repose 
Angle of repose of Duloxetine hydrochloride powder blend was found in the range of               
24º.23’ to 30°.09’. This values are well within the limit of 25º – 30° which indicates the flow 
of Duloxetine hydrochloride was excellent. The above results revealed that the all the 
formulations (F-I to F-V) possess excellent flow. 
Bulk Density and Tapped Density 
Bulk density of Duloxetine hydrochloride was found between 0.305 ± 0.3 to 0.640 ± 
0.1 g/cm
3
.   Tapped density ranges between 0.351 ± 0.5 to 0.745 ± 0.3 g/cm
3
. 
Compressibility Index and Hausner’s Ratio 
Compressibility index  values was found to be in the range of  13.11 ± 0.1 to 18.55 ± 
0.7 % and the hausner,s ratio lies between 1.15 ± 0.5 to 1.17 ± 0.3. Compressibility index of 
formulation - I belongs to fair flow and compressibility index of other formulations indicates 
that the blend belongs to good flow property.  
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5.4 EVALUATION OF DULOXETINE HYDROCHLORIDE TABLETS  
 5.4.1 POST COMPRESSION PARAMETERS  
5.4.1.1 GENERAL APPEARANCE 
The general appearance of all formulations (F-I to F-V) were examined and found as follows, 
Color – Yellow  
Shape – Round  
Surface – Smooth 
Cracks, depressions, pinholes – Absent 
The prepared tablets were evaluated for various post compression parameters. The results are 
mentioned in table: 20. 
Table: 20. Post Compression Parameters 
Formulation 
Code 
Thickness    
(mm) 
 
Hardness 
(kg /cm
2
) 
 
Weight 
Variation 
(mg) 
Friability 
(%) 
Disintegration 
(min) 
F-I 
3.22 ± 
0.055 
7.20 ± 0.32 145.50 ±1.55 0.14 ±0.007 8 min 30 sec 
F-II 
3.35 ± 
0.010 
6.60 ± 0.29 144.50 ±1.20 0.12 ±0.004      8 min 
F-III 
3.40 ± 
0.017 
7.00 ± 0.27 145.25 ±1.08 0.10 ±0.010 5 min 45 sec 
F-IV 
3.36 ± 
0.016 
7.50 ± 0.49 145.00 ± 0.13 0.16 ±0.005 7 min 30 sec 
F-V 
3.29 ± 
0.020 
7.20 ± 0.24 146.03 ± 0.12 0.12 ±0.003 9 min 30 sec 
*All the values are expressed as mean ± SD, n=3. 
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Discussion: 
Thickness and Hardness 
The thickness of tablets was found in the range of 3.22 ± 0.055 to 3.40 ± 0.017mm. 
This may be due to the presence of upper and lower punches adjustment during the 
compression process. All the formulations showed uniform thickness. Hardness of 
Duloxetine hydrochloride tablets was found in the range of 6.60 ± 0.29 to 7.50± 0.49 kg/cm
2
. 
All the formulations possessed good mechanical strength. 
Weight Variation Test 
Twenty tablets of each formulation were randomly selected for weight variation test. 
The accepted percentage deviation was ± 7.5 for 130 – 324 mg tablet weight as per I.P. The 
results showed that the weight of tablets ranges from 144.50 ± 1.20 to 146.03 ± 0.12 for all 
the formulations that is well within the I.P limit (± 7.5). Hence all the tablets passed the 
weight variation test. 
Friability Test 
The friability test carried was out by using Roche friabilator. The maximum weight 
loss should not be more than 1%. The friability values of formulations (F-I to F-V) were 
found to be in the range of 0.10 ± 0.010 to 0.16 ± 0.005% respectively. Hence all the tablets 
passed the friability test. 
Disintegration Test 
Disintegration test of Duloxetine hydrochloride uncoated tablets ranges from 5 min 45 
sec to 9 min 30 sec. The acceptable disintegration time of uncoated tablet limit as per I.P is 
NMT 15 minutes. Hence all the tablets passed the disintegration test. 
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5.4.2 ASSAY OF DULOXETINE HYDROCHLORIDE BY HPLC METHOD 
The assay was carried out by HPLC method as per the procedure given in 
methodology part. The HPLC chromatogram of Duloxetine hydrochloride standard and 
sample formulations were shown in fig no: 7 to 12 and in table: 20 respectively. 
 
*RT – Retention Time 
Fig: 7 HPLC Chromatogram of Duloxetine HCI (Standard) 
 
*RT – Retention Time 
Fig: 8 HPLC Chromatogram of Formulation F-I 
S.No. DRUG RT* Area Plate count Symmetry 
1 Duloxetine HCI 2.471 5179018 5282 0.91 
S.No. DRUG RT* Area Plate count Symmetry 
1 Formulation F-I 2.471 5178834 5282 0.91 
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*RT – Retention Time 
Fig: 9 HPLC Chromatogram of Formulation F-II 
 
*RT – Retention Time 
Fig: 10 HPLC Chromatogram of Formulation F-III 
S.No. DRUG RT* Area Plate count Symmetry 
1 Formulation F-II 2.476       5204743 5305 0.91 
S.No. DRUG RT* Area Plate count Symmetry 
1 Formulation F-III 2.481     5207273 5330 0.91 
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*RT – Retention Time 
Fig: 11 HPLC Chromatogram of Formulation F-IV 
 
*RT – Retention Time 
Fig: 12 HPLC Chromatogram of Formulation F-V 
  
S.No. DRUG RT* Area Plate count Symmetry 
1 Formulation F-IV 2.483 5210035 5335    0.91 
S.No. DRUG RT* Area Plate count Symmetry 
1 Formulation F-V 2.481 5217624 5332   0.91 
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Table: 21. Assay of Duloxetine Hydrochloride Tablets 
Formulation Code Limit (%) Assay (%) 
F-I 
90 – 110% 
99.42 
F-II 98.55 
F-III 98.70 
F-IV 102.16 
F-V 100.45 
Marketed sample 99.02 
 
Discussion: 
The content of Duloxetine hydrochloride in all formulations were found in the range of 
98.55% to 102.16% which was within the acceptable I.P limits. 
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5.4.3 STANDARD CURVE OF DULOXETINE HYDROCHLORIDE
90 
Preparation of pH 6.8 Phosphate Buffer
 
Place 7.20 gm of dihydrogen phosphate and 2.86 gm of potassium hydrogen phosphate in a     
500 ml volumetric flask and make upto 500 ml with de-mineralized water. 
Preparation of Standard Curve of Duloxetine Hydrochloride 
0.025 gm of Duloxetine hydrochloride was accurately weighed and dissolved first in 
methanol and the volume was made upto 50 ml with methanol to get a concentration of 
500µg/ml. From this 5 ml was pipetted out and transferred into a 50 ml volumetric flask and 
make upto required volume using pH 6.8 phosphate buffer to get a concentration of 50 µg/ml, 
from this is secondary stock solution different concentrations of drug (3, 5, 10, 15, 20, 25 and 
30 μg/ml) were prepared using pH 6.8 phosphate buffer. The absorbance of the resulting 
solutions were measured at 290 nm using UV spectrophotometer. Standard curve of 
Duloxetine hydrochloride was mentioned in table: 22 and fig: 13. 
Table: 22. Standard Curve Data of Duloxetine Hydrochloride 
Concentration (µg/ml) Absorbance at 290 nm 
3 0.122 
5 0.184 
10 0.410 
15 0.563 
20 0.762 
25 0.987 
30 1.20 
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Fig: 13 Calibration Curve of Duloxetine Hydrochloride 
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5.4.4 IN VITRO DISSOLUTION STUDIES 
The in vitro drug release of Duloxetine hydrochloride tablets were given in table: 23 and fig: 
14 
Table: 23. Comparative In Vitro Drug Release Studies of Duloxetine Hydrochloride 
Tablets 
Time 
(min.) 
Percentage Drug Release (%) 
Formulation Code 
F-I F-II F-III F-IV F-V 
5 6.70 ± 0.32 24.78 ± 0.32 34.97 ± 0.20 66.98 ± 0.32 93.78 ± 0.22 
10 8.78 ± 0.22 24.98 ± 0.39 36.98 ± 0.38 74.87 ± 0.21 94.67 ± 0.23 
15 9.74 ± 0.36 25.32 ± 0.32 37.87 ± 0.37 78.98 ± 0.32 96.89 ± 0.22 
20 10.96 ± 0.27 26.96 ± 0.34 43.96 ± 0.31 84.67 ± 0.16 97.78 ± 0.16 
30 11.57 ± 0.22 27.97  ± 0.22 50.78 ± 0.28 87.96 ± 0.37 99.79 ± 0.080 
45 12.57 ± 0.28 28.96 ± 0.10 64.50 ± 0.13 95.78 ±0.22 100.67 ± 0.11 
*All the values are expressed as mean ± SD, n=3. 
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Fig: 14 Comparative In Vitro Drug Release Studies of Duloxetine Hydrochloride  
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Discussion: 
1. Duloxetine hydrochloride tablets (F-I to F-V) were prepared by direct compression 
method and subjected to in vitro drug release studies. Formulation F-I showed only 
12.57% of drug release at the end of 45 min. So to increase the drug release it was 
planned to add calcium carbonate as an alkalizing agent in formulation F–II and F-III. 5% 
of calcium carbonate was added in formulation F–II and 15% in formulation F–III. But 
formulation F–II and F-III showed only 28.96% and 64.50% drug release at the end of 45 
min. So in formulation F–IV calcium carbonate content was further increased to 25%.  In 
formulation F–V 25% calcium carbonate is added. Formulation F–IV and F-V showed 
maximum drug release at the end of 45 min (95.78% and 100.67%). This may be due to 
the alkaline pH nature due to the addition of calcium carbonate in formulation F–IV and 
F-V which showed more drug release than other formulations. 
2. Hence formulation F–IV and F-V were selected as the best formulations based on drug 
release. The best formulations F-IV and F-V was coated with 5.80 mg and 11.80 mg of 
protectab enteric M1 polymer and evaluation of enteric coated tablets were performed and 
the results are given in table: 23. 
3. In comparison of formulation F-IV and F-V, the only difference is coating thickness. 4% 
coating thickness is applied in F-IV and the thickness was increased upto 8% in F-V.  
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5.4.5 EVALUATION OF DULOXETINE HYDROCHLORIDE ENTERIC COATED 
TABLETS 
Table: 24. Evaluation of Duloxetine Hydrochloride Enteric Coated Tablets 
Formulation 
Code 
Thickness 
(mm) 
Weight Variation 
(mg) 
Disintegration Time (min) 
0.1N HCl  
pH 6.8 Phosphate 
Buffer 
F-IV 3.48 ± 0.071 158.12±2.25 50 min - 
F-V 3.42± 0.026 160.50±1.90 - 15 min 30 sec 
Marketed 
Sample 
2.90± 0.055 210.00±2.50 - 15 min 40 sec 
*All the values are expressed as mean ± SD, n=3. 
Discussion: 
Formulation F–IV showed increased thickness after coating process. The weight of 
tablets also improved further upon addition of 4% coating solution. But formulation F-IV 
failed in disintegration test as it does not withstand in 0.1 N HCI for 2 hr. So in formulation 
F-V the coating thickness was further increased upon addition of 8% coating solution. 
Formulation F-V withstand in 0.1 N HCl for 2 hr and disintegrate in alkaline medium after 15 
min and 30 seconds which is almost similar compared to the marketed Duloxetine HCl 
enteric coated tablets. Hence formulation F-V was considered as best formulation and the 
drug release behavior of formulation F-V was compared with the marketed Duloxetine HCl 
enteric coated tablets. 
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5.4.6 IN VITRO DRUG RELEASE STUDIES 
The in vitro drug release of Duloxetine hydrochloride enteric coated tablets are given in table: 
25 and fig: 15. 
Table: 25. Comparative In Vitro Drug Release Data of Duloxetine Hydrochloride 
Marketed Sample and Formulation (F-V) 
All the value are expressed as mean ± SD, n=3 
  
Dissolution Medium Sampling Time 
Percentage Drug Release (%) 
F-V Marketed Sample 
0.1 N HCl 2 hr 1.20 ± 0.25 2.75 ± 0.75 
Simulated intestinal 
fluid 
(6.8 pH Phosphate 
buffer) 
5 min 10.23 ± 0.74 12.50 ± 0.85 
10 min 20.56 ± 0.28 19.20 ± 0.24 
15 min 46.29 ± 0.45 40.31 ± 0.24 
20 min 72.30 ± 0.38 70.42 ± 0.46 
30 min 85.30 ± 0.63 87.25 ± 0.53 
45 min 100.53 ± 0.85 97.98 ± 0.52 
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Fig: 15 Comparative In Vitro Drug Release Profiles of Duloxetine HCI Marketed 
Sample and Formulation (F-V) 
Discussion   
The percentage drug release of marketed sample and formulation (F-V) was found to be 
97.98±0.52% and 100.53±0.85 % at end of 2 hour and 45 minutes. 
The drug release from formulation F-V was found to be better than the marketed product.  
This may be due to increase in addition of calcium carbonate as an alkalizing agent in 
formulation    F-V. 
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5.4.7 STABILITY STUDIES  
The best formulation (F-V) was selected for the stability study and stored at 
25±2
0
C/60%±5% RH and 40±2
0
C/75% ±5% RH for 3 months. The tablets were evaluated for 
various parameters like physical appearance, average weight, thickness, hardness, 
disintegration, in vitro drug release and drug content at every one month. The results are 
presented in table: 26 and 27. 
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Table: 26. Stability Study Data of Formulation F-V Stored at 25 ± 2°C/60% ± 5% RH 
 
S. 
No. 
Storage Conditions: 25± 2°C/60%±5% RH  
Tests Initial Period 1
st  
Month 2
nd 
Month 3
rd
 Month 
1.  Physical Appearance 
Orange color, round 
shaped tablets 
Complies Complies Complies 
2.  Average Weight (mg) 160.50 160.37 160.25 160.11 
3.  Thickness (mm) 3.42 3.42 3.42 3.42 
4.  Hardness (kg/cm2) 7.10 7.20 7.26 7.28 
5.  
D
is
in
te
g
ra
ti
o
n
 
T
im
e 
(m
in
) 0.1 N HCl - - - - 
pH 6.8 
phosphate 
buffer 
15 min 30 sec 14 min 15sec 16 min  45sec 16 min 30 sec 
6.  
In
 V
it
ro
 D
is
so
lu
ti
o
n
 S
tu
d
y
 Acid 
Medium-  
120 min 
(NMT 
10%) 
1.20 ± 0.25 1.70 ± 0.65 2.50 ± 1.15 3.00 ± 1.35 
Alkaline  
medium 
(at the end 
of 45 min) 
(%) 
99.98 ± 0.52 98.99 ± 0.25 99.40 ± 0.74 98.25 ± 0.97 
7.  
Assay % 
(Limit: 90 to 110) 
100.45±1.10 99.45 ± 0.26 99.40 ± 0.96 99.52 ± 0.85 
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Table: 27. Stability Study Data of Formulation F-V Stored at 40 ± 2
0
C/75% ± 5% RH 
S. 
No. 
Storage Conditions: 40±2
0
C/75% ±5% RH 
Tests Initial Period 1
st  
Month 2
nd 
Month 3
rd
 Month 
1.  Physical Appearance 
Orange color, round 
shaped tablets 
Complies Complies Complies 
2.  
Average Weight 
(mg) 
160.50 161.25 160.89 162.53 
3.  Thickness (mm) 3.42 3.42 3.42 3.42 
4.  Hardness (kg/cm2) 7.20 7.25 6.95 6.95 
5.  
D
is
in
te
g
ra
ti
o
n
 
T
im
e 
(m
in
) 0.1 N HCl - - - - 
pH 6.8 
phosphate 
buffer 
15 min 30 sec 18 min 30sec 14 min  15sec 
 
12 min 45 sec 
6.  
  
In
 V
it
ro
 D
is
so
lu
ti
o
n
  
S
tu
d
y
 
Acid 
Medium – 
120 min 
(NMT 10%) 
1.20 ± 0.25 1.30 ± 0.25 2.86 ± 0.12 
 
3.20 ± 1.95 
Alkaline  
medium 
(at the end of 
45 min) 
(%) 
99.98 ± 0.52 98.29 ± 0.35 99.50 ± 0.94 99.55 ± 0.50 
7.  
Assay % 
(Limit: 90 to 110) 
100.45±1.10 100.27 ± 0.56 99.65 ± 0.37 99.55 ± 0.11 
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Discussion: 
Stability studies revealed that there was no significant changes found in physical 
appearance, average weight, thickness, hardness, disintegration, in vitro drug release and assay 
during the period of three months even after stored at 25±2ºC/60%±5% RH and 
40±2ºC/75%±5% RH. The study revealed that the formulation F-V was stable at 
25±2°C/60%±5%RH and 40±2ºC/75%±5% RH even after stored for three months.  
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  CHAPTER – 6  
SUMMARY AND CONCLUSION 
 The present study was undertaken to formulate and evaluate enteric coated tablets of 
Duloxetine hydrochloride using calcium carbonate as an alkalizing agent to improve the 
solubility of drug and to convert micro pH environment to alkaline nature.  
The preformulation study of API such as organoleptic properties, solubility, 
compatibility study and FT-IR drug – excipient interaction study were carried out. 
Five formulations (F-I to F-V) of Duloxetine hydrochloride tablets were prepared by 
direct compression method. 
The prepared blend was evaluated for precompression parameters like angle of 
repose, bulk density, tapped density, compressibility index and hausner’s ratio. The prepared 
tablets were evaluated for post compression parameters such as hardness, thickness, weight 
variation, friability, assay, disintegration test and dissolution study.  
From the experimental results, the following points can be summarized. 
 Preformulation studies have been performed to study the nature of API and 
compatibility of API with excipients by physical observation and FT-IR studies. The 
results showed that there was no interaction between API and all the excipients 
selected. 
 The results of micromeritic properties indicates that the flow property of all 
formulation were good. 
 All formulations possessed uniform thickness. The prepared tablets also possessed 
good mechanical strength and uniform hardness. 
 All formulations of Duloxetine hydrochloride tablets passed the weight variation, 
friability test and disintegration test. 
 The percentage drug content was found in the range of 98.55% to 102.16% for all the 
formulations, which was within the I.P acceptable limits. 
 In the in vitro dissolution study, formulation F-IV and F-V showed maximum drug 
release of 95.78% and 100.67% at the end of 45 min. 
  Hence formulation F-IV and F-V were selected for enteric coating and coated with 
protectab enteric M1 as coating polymer in different concentration. 
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 4% coating thickness was applied in formulation F-IV and 8% in formulation F-V. 
Both the formulations were evaluated for various parameters. 
 Formulation F-IV failed in disintegration test of enteric coated tablets. So formulation    
F-V was taken as best formulation and the drug release of formulation F-V was 
compared with marketed enteric coated tablet of Duloxetine hydrochloride.  
 In the comparative in vitro dissolution study, formulation F-V showed better drug 
release than the marketed product. 
  Formulation (F-V) was selected for the stability study and stored at 25±2°C/60%±5% 
RH and 40±2ºC/75%±5%RH for 3 months. The results indicated that there was no 
significant change found in appearance, thickness, weight variation, disintegration 
time, drug content and in vitro dissolution study. The study results showed that the 
formulation F-V was stable even after stored at 25±2°C/60%±5% RH and 
40±2ºC/75%±5% RH for 3 months. 
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CONCLUSION 
A total of five formulations (F-I to F-V) of Duloxetine hydrochloride tablets were 
developed by direct compression method. The work was carried out to delay the release of 
Duloxetine hydrochloride by using enteric polymer.  
From all the above observation it was concluded that the formulation F-V containing 
calcium carbonate as an alkalizing agent along with mannitol and microcrystalline cellulose 
as diluent was selected as the best formulation among the five formulations and 8% coating 
solution of Protectab enteric M1 polymer was applied as enteric coating. Formulation F-V 
showed better drug resistance in acidic medium and release the drug in alkaline medium as 
per I.P specification and showed rapid drug release in intestine than marketed Duloxetine 
hydrochloride enteric coated tablet. Hence the study concluded that formulation F-V satisfied 
all the criteria for enteric coating tablets.  
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CHAPTER- 7 
 7. FUTURE PLAN  
Formulation (F-V) may be further investigated for following studies.  
The present work may explore the following aspects in the future which may become 
valuable assets in the field of pharmaceutical science. 
 Manufacture Acid labile drug into formulations as cost effective & stable 
pharmaceutical composition. 
 The in vitro studies can be extended to in vivo studies by leading to a final conclusion 
of a successful formulation which can be marketed thereafter. 
 Duloxetine hydrochloride enteric coated tablet formulation may be evaluated for 
various pharmacokinetic parameters. 
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